Bioactive walnut peptides and compositions for topical skin treatment
Bioactive walnut peptides address the limitations of existing topical treatments by stimulating skin repair and regeneration, enhancing growth factors and reducing inflammation, thus improving skin health and appearance.
Patent Information
- Application Number
- JP2026526146
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-03-28
- Filing Date
- 2024-10-31
- Publication Date
- 2026-11-19
AI Technical Summary
Existing topical treatments fail to effectively induce the skin's intrinsic repair and regeneration mechanisms, particularly in addressing skin aging, inflammation, and barrier dysfunction, due to issues with delivery and stability of large proteins.
The use of bioactive walnut peptides, derived from walnut proteins through enzymatic, fermentation, or chemical hydrolysis, which are topically applied in compositions to stimulate growth factors, enhance autophagy, and improve mitochondrial function, thereby promoting skin repair and rejuvenation.
Bioactive walnut peptides enhance skin regeneration by increasing EGF, HGF, and TGFα production, reduce inflammation, and improve skin barrier function, leading to improved skin appearance and reduced aging effects.
Smart Images

Figure 2026539089000007 
Figure 2026539089000008 
Figure 2026539089000009
Abstract
Description
TECHNICAL FIELD
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Patent Application No. 63 / 594,586 filed on October 31, 2023, U.S. Patent Application No. 63 / 617,209 filed on January 3, 2024, French Patent Application FR2401882 filed on February 27, 2024, and French Patent Application FR2403133 filed on March 28, 2024, all of which are incorporated herein by reference in their entirety.
[0002] REFERENCE TO SEQUENCE LISTING The Sequence Listing (created on October 30, 2024, with a size of 11 kilobytes) submitted on October 31, 2024 as an XML file named "Sequence Listing" is incorporated herein by reference in accordance with 37 CFR 1.52(e)(5).
[0003] TECHNICAL FIELD The present disclosure relates to bioactive walnut peptides and the use of the walnut peptides for topical application to the skin. The walnut peptides and compositions comprising the same are useful for improving the appearance of the skin, preventing or reversing skin aging, improving skin barrier function, and treating damaged skin, inflamed skin, and skin that has been subjected to injury, disease, or invasive procedures.
BACKGROUND ART
[0004] The skin is a unique and complex organ that spreads throughout the whole body. The skin is critical for protecting the body from external threats, regulating body temperature, and preventing water loss. The skin also functions as a sensory organ and produces vitamin D. Different types of skin exist at different positions of the body. For example, facial skin is different from scalp skin, and even the skin on the palm of the hand is different from the skin on the back of the hand.
[0005] The skin is composed of three layers: the epidermis, dermis, and subcutaneous tissue, forming the endothelial system. The epidermis is the outermost layer of the skin and the first line of defense against external threats such as microorganisms. The human epidermis is mainly composed of keratinocytes, but also contains other types of cells, including melanocytes and Langerhans cells. Each of these cell types contributes to the essential role that the skin plays through its specific function. Melanocytes give the skin its characteristic color and tone. The epidermis is inherently waterproof and therefore helps maintain hydration, preventing the body from absorbing water during bathing. Unlike other cells, epidermal cells have their own regenerative capacity and can therefore heal after being injured.
[0006] The epidermis maintains homeostasis and performs important functions through a dynamic self-regeneration process. In this process, basal keratinocytes differentiate and migrate through the stratum spinosum and stratum granulosum while progressively differentiating. When keratinocytes reach the apex of the stratum granulosum, a process of terminal differentiation occurs in which keratinocytes undergo programmed cell death and flatten to become the stratum corneum. During this process, the laminar bodies of keratinocytes in the stratum granulosum fuse with the plasma membrane, releasing their main lipid content into the intercellular spaces of the developing stratum corneum. Similarly, the interaction of hydrolytic enzymes and their inhibitors, which are excreted via the laminar bodies, participates in the construction of intercellular laminar lipid structures and ultimately contributes to cell exfoliation at the apex of the skin. Simultaneously with the accumulation of extracellular lipids, important changes occur within keratinocytes during stratum corneum formation. Transglutaminase-1-mediated crosslinking of cytoplasmic proteins at the cell margin forms a highly insoluble keratinized envelope of stratum corneum cells (hereinafter referred to as keratinocytes). Next, covalent bonding of ceramide monolayers occurs to these structures, replacing the phospholipid plasma membrane of living cells. These newly formed keratinized lipid envelopes constitute a scaffold for further layering and organization of intercellular lipids. The complex structure of the stratum corneum, made from keratinocytes intercalated by polar lipids, can be likened to a brick-and-mortar wall that constitutes the permeable barrier of the stratum corneum.
[0007] To function as a permeable barrier, the epidermis must be flexible enough to allow skin movement and the treadmill-like flow of keratinocytes through continuous layers, while maintaining mechanical resistance. Intercellular junctions and cell-matrix junctions play a central role in maintaining the mechanical properties of the epidermis. Desmosomes, which interconnect the cytoskeletons of individual cells to form a superstructure, develop throughout the epidermal tissue and change their location, protein composition, and glycan distribution in response to the stage of cell differentiation and the occurrence of mechanical constraints. In this process, adherent junctions bound to the actin cytoskeleton participate in the dynamics of desmosome and adherent junction expression. When the stratum corneum is formed, these junctions cross-link to form a keratinizing envelope, contributing to the improved physical resistance of the functional stratum corneum barrier. The mechanical properties of the stratum corneum show a significant increase in hardness between the deep and superficial layers of keratinocytes. Because lateral, or transverse, adhesion between cells is stronger than adhesion between consecutive keratinocyte layers, the mechanical integrity of the stratum corneum also depends on the direction of the applied shear force.
[0008] The relative impermeability of the stratum corneum, and consequently its barrier function, is essentially dependent on intercellular lipids, even though they account for only 15% of the stratum corneum's weight. The quasi-equivalent ratios of ceramics, cholesterol, and free fatty acids appear to be prerequisites for the proper auto-assembly of the intercellular lipid multilayers within the stratum corneum. The lipid composition of the stratum corneum further differentiates into free fatty acids (10%), cholesterol (27%), cholesterol esters (10%), cholesterol sulfates (3%), and ceramides (50%). Organized into multiple bilayers parallel to the keratinocyte surface, these lipids can aggregate in regions exhibiting different densities within the layer. High-density, orthorhombic lateral packing of lipid molecules, and a more fluid hexagonal format, are dominant in normal human skin. Efficient filling of the gaps in the stratum corneum is essential to prevent excessive water loss and the intrusion of environmental contaminants / aggressive substances.
[0009] The formation and repair of a lost stratum corneum barrier is a dynamic and finely regulated process susceptible to intrinsic and environmental factors. In addition to disease conditions resulting from UV radiation or pollution and exposure to harsh environments, everyday events can also adversely affect the skin barrier. Given the importance of the stratum corneum in maintaining skin homeostasis, and considering the frequency and severity of intrinsic and extrinsic factors that can alter stratum corneum permeability, the need for topical products that support the skin barrier is emphasized. Understanding the structure, composition, and function of the epidermal permeability barrier provides a solid foundation for refining the knowledge base of topical treatments aimed at maintaining and improving the skin of patients in both healthy and diseased states. As knowledge surrounding the skin barrier continues to develop, the formulation of pharmaceutical and cosmetic compositions to improve barrier integrity has been pursued. Efforts continue to address the need for improved barrier function and barrier regeneration.
[0010] The dermis is the middle layer of skin, located immediately beneath the epidermis. It contains connective tissue, collagen, elastin, hair follicle lymph nodes, and sweat glands. The dermis provides a strong support structure for the epidermis. It is also its nourishing layer. The dermis primarily contains fibroblasts, but also contains leukocytes, mast cells, or tissue macrophages. The dermis also contains blood vessels and nerve fibers. The cell-free portion of the dermis (i.e., the intercellular area) is called the extracellular matrix. The extracellular matrix of the skin is composed of various extracellular components, including proteins, particularly collagen fibers and elastin. Other extracellular matrix components of the skin include glycosaminoglycans (e.g., hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, etc.), proteoglycans (e.g., fibromodulin, decorin, biglycan, perlecan, heparan sulfate proteoglycan 2, agrin, versican, aggrecan, lumican, type XI collagen, type XII collagen, type XIV collagen, testican 1, testican 2, etc.) and various glycoproteins (e.g., fibrillin 1, thrombospondin-1 and -2, tenacin-C and -X, osteopontin, fibronectin, laminin-5 and -6, vitronectin, etc.). These extracellular components are synthesized by dermal fibroblasts, making dermal fibroblasts the primary building blocks of the dermis's structural assembly.
[0011] The extracellular matrix is a highly heterogeneous amalgam of morphologically diverse architectural entities. In addition to regulating cellular behavior by interacting with cell surface receptors and soluble growth factors, the extracellular matrix constitutes individual tissues and confers their structural integrity. Therefore, dysfunction and alterations of extracellular matrix components can impair both tissue integrity and cellular performance. In humans, dysfunction and alterations of extracellular matrix components in skin and mucous membranes can lead to skin aging, skin atrophy, damaged skin, skin wounds, and other problems.
[0012] The subcutaneous tissue is the deepest layer of skin and consists mainly of fat and connective tissue. It connects the skin to the fascia (tissue) located beneath the bones and muscles. While not always classified as a formal layer of skin, the subcutaneous tissue still provides important functions such as storing energy, insulating the body, and preventing skin sagging. The subcutaneous tissue houses fat-storing cells that function as energy reservoirs and act as cushions against impact.
[0013] Skin ages over time, potentially resulting in wrinkles, age spots, and loss of elasticity and volume. Skin aging includes both chronological aging (endogenous aging), which is natural aging that occurs over time due to natural biological processes, and degenerative aging, which is caused by external factors such as harmful sun exposure, pollution, and dehydration. Ultraviolet light, such as UVB, has wavelengths ranging from 280 nm to 320 nm and is known to cause skin damage and accelerate aging. UVB rays stimulate reactive oxygen species (ROS) and free radicals in skin cells, which accelerate intracellular signaling pathways, including oxidative stress on biomolecules such as DNA, proteins, and lipids. Increased oxidative stress in skin cells can stimulate keratinocytes in the epidermis or fibroblasts in the dermis, potentially leading to increased expression of genes such as matrix metalloproteinases (MMPs), collagen-degrading enzymes, through a series of transformations in intracellular signaling pathways.
[0014] Many treatments are available to treat the skin to promote anti-aging benefits. For example, due to the importance of collagen in the aging process, many collagen-containing topical products have been developed. Other ingredients such as retinoic acid, vitamin C, and hyaluronic acid are used in topical formulations that help stimulate collagen synthesis. Several cosmetic procedures, such as laser skin resurfacing, are used to reduce facial wrinkles and skin irregularities. Topical administration of proteins known to inhibit one or more signaling pathways that exhibit changes in activity after UV exposure has been investigated. However, there are difficulties associated with the use of whole proteins that cannot be effectively delivered through the epidermis. Also, large proteins are unstable, difficult to formulate, and may not be effective in topical applications. Despite the numerous products and applications proposed, none of them satisfactorily induced the skin's intrinsic repair and regeneration mechanisms. [Overview of the Initiative]
[0015] This disclosure relates to bioactive walnut peptides and their use for topical application to the skin. Bioactive walnut peptides, which can be incorporated into pharmaceutical or cosmetic compositions, treat and prevent conditions that adversely affect skin aging. Furthermore, when bioactive walnut peptides are applied topically to the skin, surprisingly, age-related inflammation is reduced, epidermal growth factor (EGF), hepatocyte growth factor (HGF), and transforming growth factor alpha (TGFa) are increased, epidermal stem cell expression is promoted, autophagy is induced, and mitochondrial function is improved. It was surprising to discover that bioactive walnut peptides affect multiple physiological pathways beneficial to the skin. Due to these numerous advantages, bioactive walnut peptides and pharmaceutical and cosmetic compositions containing them are particularly suitable for preventing and treating skin aging, and for improving or reversing the effects of skin aging. In addition, they are useful for improving the skin barrier function of healthy skin and for treating damaged skin caused by diseases including physical, chemical, environmental, sunburn, and inflammation.
[0016] Walnuts are one of the most widely distributed and oldest nuts in the world. Walnuts are highly nutritious, rich in oleic acid, linoleic acid, alpha-linoleic acid, and other unsaturated fatty acids, vitamins, and protein. Due to their high lipid content, walnuts are commonly used to produce walnut oil. The residue remaining after lipid extraction contains walnut protein and other useful components, but is considered a by-product. Walnut protein is primarily composed of albumin, globulin, gliadin, and glutenin.
[0017] Bioactive walnut peptides can be derived from walnut proteins or synthesized. For example, walnut peptides can be obtained via enzymatic hydrolysis, fermentation hydrolysis, or chemical hydrolysis of walnut proteins, or synthesized, for example, by solid-phase synthesis. Particularly useful bioactive peptides according to this disclosure typically have a molecular weight of less than 6,000 daltons, sometimes less than 1,000 daltons. Such walnut peptides may have 2 to 50 amino acid residues, but typically have 2 or 3 amino acid residues to up to about 20 amino acid residues.
[0018] Preferably, bioactive walnut peptides have at least 2 or 3 to about 20 amino acid residues and exert physiologically or dermatologically positive effects on skin cells. Bioactive peptides contain amino acids linked by covalent bonds, also called amide bonds or peptide bonds, while proteins are polypeptides with a larger molecular weight (MW), i.e., more than 50 amino acid residues. Bioactive walnut peptides typically exhibit hormone- or drug-like activity and are classified based on their mode of action. Many bioactive peptides share several structural features, such as amino acid residue lengths of 2 to 20 amino acids.
[0019] Useful bioactive walnut peptides according to this disclosure often contain one or more amino acid residues selected from leucine, proline, or combinations thereof. In further embodiments, the bioactive walnut peptide contains three or more amino acid residues selected from leucine, proline, or combinations thereof. Non-limiting examples of amino acid residues within a bioactive walnut peptide containing leucine and proline include Leu-Pro-Leu (LPP), Leu-Leu-Pro, Pro-Pro-Leu (PPL), and Pro-Leu-Pro (PLP). Further non-limiting examples of amino acid sequences that may be contained in a bioactive walnut peptide include Thr-Trp-Leu-Pro-Leu-Pro-Arg (TWLPLPR), Tyr-Val-Leu-Leu-Pro-Ser-Pro-Lys (YVLLPSPK), Lys-Val-Pro-Pro-Leu-Leu-Tyr (KVPPLLY), and combinations thereof.
[0020] In various embodiments, one or more of the following bioactive walnut peptides are preferred: Peptide I Thr-Trp-Leu-Pro-Leu-Pro-Arg (TWLPLPR), Peptide II Tyr-Val-Leu-Leu-Pro-Ser-Pro-Lys(YVLLPSPK) and / or Peptide III Lys-Val-Pro-Pro-Leu-Leu-Tyr (KVPPLLY).
[0021] As previously stated, bioactive walnut peptides are particularly useful for topical application to the skin. Therefore, this disclosure covers the use of bioactive walnut peptides in methods for treating the skin. In various embodiments, one or more bioactive walnut peptides are applied to the skin in a pharmaceutical or cosmetic composition, which typically comprises a physiologically acceptable carrier, e.g., water and optionally a water-soluble solvent. The pharmaceutical or cosmetic composition contains an amount of one or more bioactive walnut peptides sufficient to ensure that a therapeutically effective amount of one or more walnut peptides is delivered to the skin during use.
[0022] Bioactive walnut peptides are useful for treating age-related inflammation. For example, bioactive walnut peptides surprisingly and advantageously reduce, treat, or prevent inflammatory cytokines in the skin. Inflammatory cytokines are among the first factors produced in response to skin damage, and regulate the function of immune cells in epithelialization. In various embodiments, the bioactive peptides of the present disclosure prevent or downregulate the production, release, or abundance of interleukin-6 (IL-6), interleukin-8 (IL-8), or combinations thereof.
[0023] Bioactive walnut peptides are useful for stimulating skin cells called fibroblasts, which produce collagen and elastin to impart skin clarity, thickness, and firmness. Growth factors are of great importance for the regulation of cellular processes in the human body, including the skin. The bioactive walnut peptides of the present disclosure are useful for enhancing the production, release, and abundance of epidermal growth factor (EGF). EGF is a repair compound that signals cells to increase the production of collagen and elastin. This aids in cell repair and regeneration, resulting in a more lustrous and youthful complexion. In addition, bioactive walnut peptides are useful for enhancing the production, release, and abundance of hepatocyte growth factor (HGF). Increasing HGF improves tissue fibrosis and reverses the imbalance in collagen metabolism. Finally, bioactive walnut peptides are useful for enhancing the production, release, and abundance of transforming growth factor alpha (TGFa or TGF-α). TGFa is a transforming growth factor that functions as a ligand for the epidermal growth factor receptor, and activates signaling pathways for cell proliferation, differentiation, and development. Therefore, increasing TGFa can promote skin rejuvenation and repair.
[0024] In a further embodiment, the bioactive walnut peptides of the present disclosure are useful for enhancing, inducing, and increasing autophagy in the skin, for example in senescent fibroblasts. Senescent cells are characterized by lacking proliferative capacity. Senescent cells tend to accumulate with age and contribute to age-related skin changes and pathologies. Inducing autophagy allows the body to destroy and metabolize damaged or excess cellular components that arise in intracellular vacuoles. A natural reduction in autophagy occurs with aging. Accordingly, restoration or induction of autophagy helps to improve skin health and prevent premature skin aging, such as skin aging caused by sun damage.
[0025] Due to their biological activity properties, including those described above, the bioactive walnut peptides are useful in methods for improving the appearance of the skin; reducing, treating or preventing age-related skin inflammation and skin conditions associated with age-related inflammation; promoting fibroblast migration; enhancing hyaluronic acid synthesis and increasing or promoting the synthesis or abundance of collagen, elastin, and / or fibronectin; improving skin elasticity; promoting skin autophagy; as well as combinations thereof.
[0026] In a further embodiment, the bioactive walnut peptides are useful in one or more methods for depigmenting the skin, whitening the skin, making the skin appear brighter, treating pigmentation, and treating melasma-affected skin. Similarly, the bioactive walnut peptides are useful in methods for evening skin tone.
[0027] In various embodiments, the use of two or more bioactive walnut peptides is preferred. The two or more bioactive walnut peptides may have similar activities or provide different activities beneficial to the skin. In further embodiments, the use of three or more bioactive walnut peptides is preferred. The use of multiple bioactive peptides allows for the modulation of multiple physiological mechanisms in skin treatment. For example, one or more bioactive walnut peptides may be useful for preventing and / or treating age-related inflammation, and another bioactive walnut peptide may be useful for stimulating fibroblasts that produce collagen and elastin, resulting in skin clarity, thickness, and firmness. Furthermore, combinations of bioactive walnut peptides can interact synergistically, yielding benefits exceeding the sum of the individual contributions of the peptides. For example, the synergistic activity of a combination may be at least 5%, at least 10%, or at least 25% greater than the sum of the individual activities of the corresponding amounts of bioactive walnut peptides.
[0028] One or more bioactive walnut peptides are often incorporated into pharmaceutical or cosmetic compositions for application to the skin. These pharmaceutical and cosmetic compositions typically comprise one or more bioactive walnut peptides and one or more physiologically acceptable carriers, such as water. Non-limiting examples of physiologically acceptable carriers include water, water-soluble solvents such as alcohols, polyols, and glycols, and fatty compounds such as oils, triglycerides, fatty acids, and fatty alcohols. Pharmaceutical and cosmetic compositions may include lotions, creams, serums, sprays, emulsions, gels, powders, dispersions, ointments, sticks, pastes, and foams. [Brief explanation of the drawing]
[0029] Implementations of this technology will be described by referring to the attached drawings, merely as examples.
[0030] [Figure 1A]Figure 1(a) shows the concentrations of interleukin-6 (IL-6) released from adult dermal-derived human fibroblasts in response to treatment with 100 μM and 250 μM peptides I, II, and III. [Figure 1B] Figure 1(b) shows the concentrations of interleukin-8 (IL-8) released from adult dermal-derived human fibroblasts in response to treatment with 100 μM and 250 μM peptides I, II, and III. [Figure 2A] Figure 2(a) shows the amount of epidermal growth factor (EGF) produced by human epidermis reconstituted in response to treatment with 250 μM peptides I, II, and III, and combinations thereof. [Figure 2B] Figure 2(b) shows the amount of hepatocyte growth factor (HGF) produced by reconstituted human epidermis in response to treatment with 250 μM peptides I, II, and III, and combinations thereof. [Figure 2C] Figure 2(c) shows the amount of transforming growth factor alpha (TGFa) produced by human epidermis reconstituted in response to treatment with 250 μM peptides I, II, and III, and combinations thereof. [Figure 3] [Figure 4] Figure 4 shows the average intensity of activated mitochondria in adult dermal-derived human fibroblasts in response to treatment with 250 μM peptide I, peptide II, peptide III, and combinations thereof. [Figure 5-1] Figure 5 is a heatmap showing genes that were expressed differently in adult human epidermal keratinocytes treated with walnut peptide. [Figure 5-2] Figure 5 is a heatmap showing genes that were expressed differently in adult human epidermal keratinocytes treated with walnut peptide. [Figure 6] Figure 6 is a heatmap showing genes that were expressed differently in reconstituted human epidermis treated with walnut peptide. [Figure 7] Figure 7 shows the histological analysis of skin samples, including control skin samples, skin samples treated with microneedles, and skin samples treated with microneedles and walnut peptides. [Figure 8] Figure 8 shows the histological analysis of skin samples, including a control skin sample, a skin sample treated with a cell stimulation cocktail (CSC), and a skin sample treated with CSC and walnut peptide.
[0031] Various aspects of this disclosure are not limited to the results, arrangements, and representations shown in the drawings. [Modes for carrying out the invention]
[0032] This disclosure relates to bioactive walnut peptides and their topical use for treating skin. Bioactive walnut peptides contain two to several dozen amino acids linked to each other through peptide bonds. Their molecular weight is typically less than 6,000 daltons, preferably less than 3,000 daltons, and more preferably less than 1,000 daltons. The term “peptide” as used herein refers to a compound that contains an uninterrupted sequence of at least two amino acids within its structure and has a maximum of about 50 amino acids. The term “dipeptide” as used herein refers to a compound that contains an uninterrupted sequence of two amino acids within its structure. As used herein, the term "tripeptide" refers to a compound that contains a continuous sequence of three amino acids within its structure. As used herein, the term "tetrapeptide" refers to a compound that contains a continuous sequence of four amino acids within its structure. These amino acids are shown herein from left (N-terminus) to right (C-terminus) using the conventional single-letter nomenclature. In this nomenclature, G is glycine, H is histidine, K is lysine, E is glutamic acid, and so on, according to the nomenclature well known and accepted in the art.
[0033] For the purposes of this disclosure, “bioactive” peptides have a minimum of 2 or 3 amino acid residues and a maximum of approximately 20 amino acid residues and have a measurable physiological effect on skin cells. Bioactive peptides contain amino acids linked by covalent bonds, also called amide bonds or peptide bonds, while proteins are polypeptides with higher molecular weights (MW) and typically more than 50 amino acid residues. Bioactive peptides usually exhibit hormone- or drug-like activity and are classified based on their mode of action. Many bioactive peptides share several structural features, including peptide residue lengths of, for example, 2 to 20 amino acids.
[0034] As used herein, the term “amino acid” includes, and encompasses, all naturally occurring amino acids, in their D or L forms if optically active, as well as known unnatural, synthetic, and modified amino acids such as homocysteine, ornithine, norleucine, and p-valine. A list of unnatural amino acids can be found in The Peptides, Vol. 5 (1983), Academic Press, Chapter VI, by D.C. Roberts and F. Vellaccio, which is incorporated herein by reference in its entirety. The amino acids in the peptides of the present invention may be present in their natural L form, unnatural D form, or in racemic mixtures.
[0035] As used herein, the term "peptide" also refers to peptide salts, deprotected peptides, acylated forms of peptides, deacylated forms of peptides, enantiomers, diastereomers, racemates, prodrugs, and hydrates of the peptides described above. Diastereomers of peptides are obtained when the stereochemical or chiral centers of one or more amino acids are altered. Enantiomers have opposite stereochemistry at all chiral centers. In various embodiments, the C-terminus of a peptide is synthesized as an amide that neutralizes the negative charge generated by the C-terminal COOH. Such modifications can be added to help prevent enzymatic degradation.
[0036] The term "prodrug" refers to any precursor compound capable of producing or releasing the above peptides under physiological conditions. Such prodrugs are, for example, larger peptides that are selectively cleaved to form the peptides of the present invention. Further prodrugs are protected amino acids having protecting groups on the carboxylic acid and / or amino groups. Suitable protecting groups for amino groups include, for example, benzyloxycarbonyl, t-butyloxycarbonyl (Boc), formyl, and acetyl or acyl groups. Suitable protecting groups for carboxylic acid groups are esters such as benzyl esters or t-butyl esters.
[0037] Epidermal disorders can result from acute injury or exposure. Whether congenital or acquired, virtually all epidermal dysfunction is associated with a significant alteration of the permeable barrier. This is particularly evident in skin diseases with significant inflammatory components. Often, barrier dysfunction can be the origin of skin disease, as in atopic dermatitis, contributing to a vicious cycle of the given pathology through the induction of inflammatory responses. Insufficient expression of the epidermal protein filaggrin, resulting from loss-of-function gene mutations, has been found to be responsible for the development of atopic dermatitis in up to 50% of cases in Northern Europe.
[0038] Filaggrin is produced in granular layer keratinocytes, and its catabolic process in the stratum corneum results in an abundance of hydrophilic amino acids that constitute the bulk of so-called natural moisturizing factors (NMF). The absence or significant reduction of NMF impairs the hydration state of the stratum corneum, resulting in impaired barrier function. Interestingly, the same filaggrin mutation present on both gene alleles leads to the phenotype of ichthyosis vulgaris, which is most often associated with atopic dermatitis. In ichthyosis, the epidermis must compensate for the barrier breached by hyperkeratosis. The accumulation of keratinocytes is likely promoted, particularly by low stratum corneum hydration, which may inhibit the activity of hydrolytic keratinocyte enzymes. This proposed mechanism, due to the more basic (optimal) intracellular pH in amino acid-deficient tissues, may excessively drive the desquamation-promoting conditions of serine protease activation. Nanomechanical and ultrastructural analysis of the elastic properties of filaggrin-deficient keratinocytes reveals a significant reduction in cell stiffness and delayed corneodesmosome degradation. These are both potential indicators of corneal layer functionality. In addition to changes in filaggrin expression, atopic dermatitis epidermis also shows a significant decrease in major TJ proteins and, most importantly, ceramides, including ceramide EOS.
[0039] Regarding ceramide changes, apart from filaggrin mutations, decreased levels and shortening of their acyl chains were observed in non-lesion skin of atopic dermatitis. This appears to have etiological significance. Changes in ceramide expression levels, both their layered and lateral structures, correlate with disease activity. Atopic dermatitis lesions have been reported to exhibit even greater decreases in ceramide levels and free sterols, accompanied by increases in sphingosine and sphinganin-based ceramides.
[0040] In psoriasis, inflammatory skin lesions induced by interleukin-23-mobilized Th17 lymphocytes are characterized by keratinocyte hyperproliferation and incomplete terminal differentiation, which impairs permeable barrier function. Although the immune cell subsets and cytokines involved in the pathogenesis of atopic dermatitis and psoriasis differ significantly, the harmful vicious cycle of barrier disruption / inflammation still exists in the latter. Incomplete terminal differentiation of lesional keratinocytes in psoriasis is induced by T lymphocyte-mediated skin inflammation and significantly affects ceramide expression compared to normal or non-lesioned skin. Similar to atopic dermatitis, ceramide species in psoriatic lesions exhibit shorter fatty acid chains. Observations of improvement in psoriatic lesions under simple occlusion and improvement in atopic dermatitis lesions with topical emollient therapy alone clearly indicate that restoration or compensation of the stratum corneum barrier helps to break the vicious cycle of pathogenic autoproliferation.
[0041] To perform its protective function, the epidermis needs to continuously adapt to changes in environmental conditions. This includes climate / seasonal factors such as relative humidity, ambient temperature, and sun exposure, as well as environmental damage resulting from the widespread use of chemicals, the presence of air pollutants, and changes in the composition and importance of the skin surface microbiome, the latter of which are closely related to the aforementioned factors.
[0042] Moisture influences the turnover of the corneal layer by altering the rate of desquamation of keratinocytes. In fact, moisture promotes a rapid increase in the pH of the stratum corneum, resulting in increased activity of kallikrein, the major stratum corneum serine protease involved in desquamation. Exposure to water also facilitates the accessibility of corneodesmosomes to proteolytic enzymes that would otherwise remain largely contained within the hydrophobic extracellular space, thus promoting the release of cells to the skin surface. Conversely, retention of corneodesmosomes is observed in the outer stratum corneum of dry winter skin compared to normal skin. Furthermore, cold, dry climates are known to increase the prevalence and risk of flares in patients with atopic dermatitis.
[0043] Environmental factors that cause impaired skin barrier function include exposure to irritants and allergens. In industrialized societies, the skin barrier is affected by the routine use of detergents and disinfectants, combined with the harmful effects of air pollutants, which vary depending on geographical location and source. These pollutants include solid and liquid particles suspended in the air, as well as various gases such as ozone, nitrogen oxides, volatile organic compounds, and carbon monoxide. The number, size, shape, surface area, and chemical composition of particles vary, and both particles and gases can have different solubility and toxicity. Occupational factors also influence the risk, increasing it in certain subpopulations. In healthcare occupations, excessive use of gloves leads to occlusion, which significantly exacerbates the adverse effects of detergents / soaps on skin barrier function. Published data indicate that a dose-response relationship is important regarding the duration of occlusion. This is particularly relevant in workplaces where the transition between glove use and handwashing is common.
[0044] This disclosure includes methods for treating skin, comprising topical application of one or more bioactive walnut peptides in therapeutically effective amounts to the skin. In various embodiments, one or more bioactive walnut peptides have a molecular weight of less than 10,000 daltons. In further embodiments, one or more bioactive walnut peptides have molecular weights of less than 8,000 daltons, less than 6,000 daltons, less than 5,000 daltons, less than 4,000 daltons, less than 3,000 daltons, less than 2,000 daltons, less than 1,000 daltons, and optionally less than 500 daltons. Preferably, one or more bioactive walnut peptides have a molecular weight of less than 5,000 daltons, more preferably less than 2,000 daltons, and even more preferably less than 1,000 daltons.
[0045] This disclosure also relates to methods for improving the barrier function of the skin. Such methods include treating the skin by topically applying one or more therapeutically effective amounts of bioactive walnut peptides to the skin. In various embodiments, one or more bioactive walnut peptides have a molecular weight of less than 10,000 daltons. In further embodiments, one or more bioactive walnut peptides have molecular weights of less than 8,000 daltons, less than 6,000 daltons, less than 5,000 daltons, less than 4,000 daltons, less than 3,000 daltons, less than 2,000 daltons, less than 1,000 daltons, and optionally less than 500 daltons. Preferably, one or more bioactive walnut peptides have a molecular weight of less than 5,000 daltons, more preferably less than 2,000 daltons, and even more preferably less than 1,000 daltons.
[0046] The number of amino acid residues in one or more bioactive walnut peptides varies and may be limited based on the molecular weight as described above. However, in various embodiments, one or more bioactive walnut peptides contain 2 to about 50 amino acid residues. In further embodiments, one or more bioactive peptides have 2 to about 25 amino acid residues, about 2 to about 20 amino acid residues, about 2 to about 18 amino acid residues, about 2 to about 15 amino acid residues, about 2 to about 12 amino acid residues, about 2 to about 10 amino acid residues, about 3 to about 25 amino acid residues, about 3 to about 20 amino acid residues, about 3 to about 18 amino acid residues, about 3 to about 18 amino acid residues, about 3 to about 15 amino acid residues, about 3 to about 12 amino acid residues, or about 3 to about 10 amino acid residues. Preferably, one or more bioactive peptides contain 2 to 20 amino acid residues, more preferably 2 to about 15 amino acid residues, and even more preferably 3 to about 12 amino acid residues.
[0047] In various embodiments, one or more bioactive walnut peptides comprise one or more amino acid residues selected from leucine, proline, and combinations thereof. In further embodiments, one or more bioactive walnut peptides comprise three or more amino acid residues selected from leucine, proline, or combinations thereof. Non-limiting examples of bioactivity of three or more amino acid residues selected from leucine, proline, and combinations thereof include Leu-Pro-Leu, Leu-Leu-Pro, Pro-Pro-Leu, and Pro-Leu-Pro. For example, one or more bioactive walnut peptides may comprise amino acid sequences selected from Thr-Trp-Leu-Pro-Leu-Pro-Arg, Tyr-Val-Leu-Leu-Pro-Ser-Pro-Lys, or Lys-Val-Pro-Pro-Leu-Leu-Tyr. As already mentioned, bioactive walnut peptides include salts of specific amino acid sequences, deprotected forms, acylated forms, deacylated forms, enantiomers, diastereomers, racemates, prodrugs, and hydrates.
[0048] In preferred embodiments, at least one, preferably all, of one or more bioactive walnut peptides are selected from peptides I, II, and III, comprising their salts, deprotected forms, acylated forms, deacylated forms, enantiomers, diastereomers, racemates, prodrugs, and hydrates. Peptide I TWLPLPR(Thr-Trp-Leu-Pro-Leu-Pro-Arg), Peptide II YVLLPSPK(Tyr-Val-Leu-Leu-Pro-Ser-Pro-Lys), and Peptide III KVPPLLY(Lys-Val-Pro-Pro-Leu-Leu-Tyr).
[0049] In various embodiments, the use of two or more bioactive walnut peptides is desirable. Two or more bioactive walnut peptides may share similar activity or may provide different activities beneficial to the skin. In further embodiments, the use of three or more bioactive walnut peptides is preferred. The use of multiple bioactive peptides allows for reliance on multiple physiological mechanisms for skin treatment. For example, one or more bioactive walnut peptides may be useful for preventing and / or treating age-related inflammation, and another bioactive walnut peptide may be useful for stimulating fibroblasts that produce collagen and elastin, giving skin clarity, thickness, and firmness. Furthermore, as will be discussed later, combinations of bioactive walnut peptides interact synergistically, providing benefits that exceed the sum of the individual contributions of the peptides. For example, the synergistic activity of a combination of bioactive walnut peptides may be at least 5%, preferably at least 10%, and more preferably at least 25%, greater than the sum of the individual activities of the corresponding bioactive walnut peptides.
[0050] Combinations of peptide I, peptide II, and peptide III are particularly useful. For example, combinations of peptide I and peptide II, peptide I and peptide III, peptide II and peptide III, or combinations of peptide I, peptide II, and peptide III can be used. The peptides in these combinations may be included in various weight ratios relative to each other, as will be described later.
[0051] Peptide I and Peptide II can be used together in a weight ratio of about 1:10 to about 10:1. In further embodiments, Peptide I and Peptide II can be used together in a weight ratio of about 8:1 to about 1:8, about 5:1 to about 1:5, about 4:1 to about 1:4, about 3:1 to about 1:3, about 2:1 to about 1:2, or about 1:1.
[0052] Peptide I and Peptide III can be used together in a weight ratio of about 1:10 to about 10:1. In further embodiments, Peptide I and Peptide III can be used together in a weight ratio of about 8:1 to about 1:8, about 5:1 to about 1:5, about 4:1 to about 1:4, about 3:1 to about 1:3, about 2:1 to about 1:2, or about 1:1.
[0053] Peptide II and Peptide III can be used together in a weight ratio of about 1:10 to about 10:1. In further embodiments, Peptide II and Peptide III can be used together in a weight ratio of about 8:1 to about 1:8, about 5:1 to about 1:5, about 4:1 to about 1:4, about 3:1 to about 1:3, about 2:1 to about 1:2, or about 1:1.
[0054] Bioactive walnut peptides are useful for treating age-related inflammation and for preventing, reducing, and even reversing the effects of skin aging. Bioactive walnut peptides advantageously reduce, treat, or prevent inflammatory cytokines in the skin. Inflammatory cytokines are among the first factors produced in response to skin damage and regulate the function of immune cells in epithelialization. In various embodiments, the bioactive peptides of this disclosure prevent the production, release, or abundance of interleukin-6 (IL-6), interleukin-8 (IL-8), or combinations thereof.
[0055] Bioactive walnut peptides are useful for stimulating skin cells called fibroblasts, which produce collagen and elastin to give skin clarity, thickness, and firmness. Growth factors are crucial for regulating cellular processes in the human body, including the skin. In particular, the bioactive walnut peptides of this disclosure are useful for enhancing the production, release, and abundance of epidermal growth factor (EGF). EGF is a repair compound that signals cells to increase the production of collagen and elastin. This helps in cell repair and regeneration, resulting in a more radiant and youthful complexion. In addition, bioactive walnut peptides are also useful for enhancing the production, release, and abundance of hepatocyte growth factor (HGF). Increasing HGF improves histofibrosis and reverses imbalances in collagen metabolism. Finally, bioactive walnut peptides are useful for enhancing the production, release, and abundance of transforming growth factor alpha (TGFa or TGF-α). TGFa is a transforming growth factor that functions as a ligand for the epidermal growth factor receptor and activates signaling pathways for cell proliferation, differentiation, and development. Therefore, increasing TGFa can promote skin rejuvenation and repair.
[0056] In further embodiments, bioactive walnut peptides are useful, for example, to enhance, induce, or increase autophagy in senescent fibroblasts. Senescent cells are characterized by their lack of proliferative capacity. Senescent cells tend to accumulate with age and contribute to age-related skin changes and pathologies. Inducing autophagy allows the body to destroy and metabolize damaged or excess cellular components that occur in vacuoles within cells. A natural decrease in autophagy occurs with age. Thus, the restoration of autophagy using the bioactive peptides of this disclosure contributes to the improvement or prevention of premature skin aging, such as skin aging caused by sun damage.
[0057] Due to its bioactive properties, including those described above, bioactive walnut peptides are useful in methods for improving the appearance of the skin; reducing, treating, and / or preventing skin aging and / or the effects of skin aging; increasing fibroblast proliferation; stimulating epithelial cell proliferation, motility, morphogenesis, and / or angiogenesis; promoting fibroblast migration; increasing the abundance or synthesis of hyaluronic acid, and / or increasing the synthesis or abundance of collagen, elastin, and / or fibronectin; improving skin elasticity; and / or improving autophagy of skin fibroblasts.
[0058] In further embodiments, bioactive walnut peptides are useful in one or more ways for decolorizing skin, whitening skin, making skin appear brighter, treating hyperpigmentation, and treating melasma. Similarly, bioactive walnut peptides are useful in ways for evening out skin tone. Bioactive walnut peptides or compositions containing them can be applied to hyperpigmentation, melasma, solar lentigines, senile lentigines, discolored spots, skin with uneven tone, etc. In certain embodiments, a method for whitening or evening out skin tone is disclosed, comprising applying one or more bioactive walnut peptides or a cosmetic composition containing one or more bioactive walnut peptides to the skin. This method may further include identifying a person who needs to whiten or evening out their skin tone. The method may further include inhibiting melanin formation in skin cells, inhibiting tyrosinase or tyrosinase synthesis in skin cells, or inhibiting melanin transport to keratinocytes in skin cells. One or more bioactive walnut peptides or cosmetic compositions containing one or more bioactive walnut peptides can act as alpha-melanin-stimulating hormone antagonists. One or more bioactive walnut peptides or cosmetic compositions containing one or more bioactive walnut peptides can homogenize skin pigmentation. In a non-limiting embodiment, skin whitening may include reducing the appearance of senile lentigines, skin discoloration, or freckles by topical application of the composition to skin having senile lentigines, skin discoloration, or freckles.
[0059] Also disclosed is a method for treating hyperpigmentation, comprising applying one or more bioactive walnut peptides or a cosmetic composition containing one or more bioactive walnut peptides to the skin. This method may further include identifying persons who require treatment for hyperpigmentation. Additional methods intended include methods for reducing the appearance of age spots, skin discoloration, or freckles, for reducing or preventing the appearance of fine wrinkles or creases, or for increasing skin firmness.
[0060] In another embodiment, a method is disclosed for reducing the appearance of uneven skin tone, comprising topically applying one or more bioactive walnut peptides or cosmetic compositions containing one or more bioactive walnut peptides to the skin. Uneven skin tone can be caused by skin discoloration. One or more bioactive walnut peptides or cosmetic compositions containing one or more bioactive walnut peptides can be applied to discolored skin (e.g., skin of the face, skin of the upper limbs, skin of the lower limbs, scalp, skin of the neck, skin of the chest, skin of the abdomen, skin of the hands, etc.). Discolored skin may include age spots, blemishes, freckles, hyperpigmented skin, skin with melasma, skin that has been excessively exposed to sunlight, etc. The method can also be used to improve the skin tone of a person by topically applying one or more bioactive walnut peptides or cosmetic compositions containing one or more bioactive walnut peptides disclosed throughout this specification to skin having skin discoloration. This method can also be used to prevent the appearance of uneven skin tone by applying the compositions disclosed throughout this specification topically to skin at risk of developing uneven skin tone. Skin at risk of developing uneven skin tone includes skin excessively exposed to sunlight, pregnant women, people with or at risk of developing melasma, and post-inflammatory hyperpigmentation (e.g., darkening of the skin after skin damage such as acne lesions or burns). One or more bioactive walnut peptides of the present invention or cosmetic compositions comprising one or more bioactive walnut peptides can also be used to whiten skin.
[0061] In various embodiments, this disclosure relates to the use of one or more bioactive walnut peptides, or a pharmaceutical or cosmetic composition containing one or more bioactive walnut peptides, for improving skin barrier function or skin re-epithelialization. Accordingly, this disclosure encompasses methods for improving skin barrier function or skin re-epithelialization, which include applying a therapeutically effective amount of one or more bioactive walnut peptides or a composition containing them to skin, including damaged and undamaged skin.
[0062] In various embodiments, the Disclosure relates to the use of one or more bioactive walnut peptides, or a pharmaceutical or cosmetic composition containing one or more walnut peptides, for treating or repairing damaged skin. Accordingly, the Disclosure encompasses methods for treating or repairing damaged skin, which include applying a therapeutically effective amount of one or more bioactive walnut peptides or a composition containing them to skin in need. In further embodiments, the damaged skin is damaged as a result of physical, chemical, environmental, sun exposure, or disease.
[0063] In further embodiments, the disclosure relates to the use of one or more bioactive walnut peptides, or pharmaceutical or cosmetic compositions comprising one or more bioactive walnut peptides, for wound healing. For example, the disclosure covers methods for improving wound healing as a result of the wound healing properties conferred by bioactive walnut peptides and compositions comprising them, and methods for treating or improving the appearance of skin. Such methods include (i) damaging skin tissue using chemicals, lasers, or physical force, and (ii) applying a therapeutically effective amount of one or more bioactive walnut peptides to the damaged skin. Non-limiting examples of cosmetic treatments that damage the skin include ablative laser treatment, non-ablative laser treatment, microneedling treatment, cryotherapy treatment, radiofrequency microneedling treatment, dermabrasion, chemical peeling, exfoliants, or mechanical or energy-based devices, or any chemical treatment that damages the skin (e.g., chemical peeling).
[0064] In various embodiments, this disclosure relates to the use of one or more bioactive walnut peptides, or a pharmaceutical or cosmetic composition containing one or more walnut peptides, for improving skin barrier function. Accordingly, this disclosure encompasses methods for improving skin barrier function, including applying one or more bioactive walnut peptides or compositions containing them in therapeutically effective amounts to skin in need. In various embodiments, skin barrier function of healthy, undamaged skin is improved. In other embodiments, skin barrier function of damaged skin is improved.
[0065] In various embodiments, the Disclosure relates to the use of one or more bioactive walnut peptides, or a pharmaceutical or cosmetic composition containing one or more walnut peptides, for treating dry or itchy skin. Accordingly, the Disclosure encompasses methods for treating dry or itchy skin, including applying a therapeutically effective amount of one or more bioactive walnut peptides, or a composition containing them, to skin in need.
[0066] In various embodiments, the present disclosure relates to the use of one or more bioactive walnut peptides, or a pharmaceutical or cosmetic composition comprising one or more bioactive walnut peptides, for treating skin conditions, diseases, or disorders selected from psoriasis, dermatitis, atopic dermatitis, allergic dermatitis, eczema, spongy conditions, edema, hereditary ichthyosis, senile xerosis, palmar keratosis, plantar keratosis, wounds, contusions, pore size, skin cancer, impaired healing or re-epithelialization, keloids, hypertrophic scars, cellulitis, orange peel skin, increased elasticity, increased photoelasticity, keratosis, acne erythematous, tubulodilator, telangiectasia, or a combination thereof. Accordingly, the present disclosure includes methods for treating a skin condition, disease, or disorder selected from psoriasis, dermatitis, atopic dermatitis, allergic dermatitis, eczema, spongiform eczema, edema, hereditary ichthyosis, senile xerosis, palmar hyperkeratosis, plantar hyperkeratosis, wounds, bruises, pore size, skin cancer, impaired healing or re-epithelialization, keloids, hypertrophic scars, cellulitis, orange peel skin, increased elasticity, increased photoelasticity, keratosis, acne erythematous, tubulodilator, telangiectasia, or a combination thereof, comprising applying a therapeutically effective amount of one or more bioactive walnut peptides or compositions containing them to the skin in need.
[0067] In further embodiments, the disclosure relates to the use of one or more bioactive walnut peptides, or pharmaceutical or cosmetic compositions comprising one or more bioactive walnut peptides, for treating skin affected by inflammation or inflammatory disorders, and to methods for treating skin affected by inflammation or inflammatory disorders. Non-limiting examples of inflammatory disorders include atopic dermatitis, psoriasis, or a combination thereof.
[0068] In various embodiments, the disclosure relates to the use of one or more bioactive walnut peptides, or a pharmaceutical or cosmetic composition comprising one or more walnut peptides, for enhancing terminal differentiation and keratinization of skin cells. Similarly, the disclosure relates to a method for enhancing terminal differentiation and keratinization of skin cells, the method comprising applying a therapeutically effective amount of one or more bioactive walnut peptides to skin in need.
[0069] One or more bioactive walnut peptides are often incorporated into pharmaceutical or cosmetic compositions for application to the skin. Pharmaceutical and cosmetic compositions typically comprise one or more bioactive walnut peptides and a physiologically acceptable carrier. As used herein, “physiological carrier” is a carrier suitable and safe for application to human skin. A particularly common physiologically acceptable carrier is water. However, physiologically acceptable carriers can also be oils, fats, organic solvents, etc., as long as they are suitable and safe for application to the skin. Non-limiting examples of physiologically acceptable carriers include water, water-soluble solvents such as alcohols, polyols, and glycols, and fatty compounds such as oils, triglycerides, fatty acids, and fatty alcohols. The pharmaceutical and cosmetic compositions of this disclosure may be lotions, creams, serums, sprays, emulsions, gels, powders, dispersions, ointments, sticks, pastes, or foams.
[0070] One or more bioactive walnut peptides are often combined with one or more additional dermatolytic agents. Non-limiting examples of dermatolytic agents include anti-atrophic agents, antioxidants, depigmentants, or combinations thereof. Specific but non-limiting examples include ceramides, Melacil® (N-[(1,2-dihydro-2-thioxo-3-pyridinyl)carbonyl]glycine, INCI:2-mercaptonitinoylglycine), alpha hydroxy acids, beta hydroxy acids, vitamin A, vitamin C, vitamin D, vitamin E, niacinamide, caffeine, ferulic acid, salicylic acid, madecassoside, retinoic acid, benzoyl peroxide, or combinations thereof. In preferred embodiments, one or more bioactive walnut peptides are combined with one or more ceramides, for example, free ceramides, such as ceramide EOP, ceramide AS, ceramide AP, ceramide NS, ceramide NP, ceramide NH, ceramide AH, ceramide EOH, ceramide EOS, ceramide AdS, ceramide NdS, ceramide EOdS, protein-bound ceramides, phytosphingosine, sphingosine, ceramide precursors, fatty acids, fatty alcohols, cholesterol, cholesterol sulfate, or combinations thereof.
[0071] One or more bioactive walnut peptides can be combined with cholesterol.
[0072] One or more bioactive walnut peptides may be combined with one or more sphingolipids. Sphingolipids are a type of lipid that contains a sphingoid base backbone, which is a set of aliphatic amino alcohols containing sphingosine. One or more walnut peptides may be combined with sphingosine-1-phosphate.
[0073] In preferred embodiments, one or more bioactive walnut peptides reduce, treat, or prevent the production, release, or abundance of inflammatory cytokines in the skin, such as interleukin-6 (IL-6), interleukin-8 (IL-8), or combinations thereof.
[0074] In preferred embodiments, one or more bioactive walnut peptides enhance the production, release, or abundance of epidermal growth factor (EGF), hepatocyte growth factor (HGF), and / or transforming growth factor alpha (TGFa) in the skin.
[0075] In preferred embodiments, one or more bioactive walnut peptides enhance or upregulate autophagy in skin cells, such as senile or aging fibroblasts.
[0076] In preferred embodiments, one or more bioactive walnut peptides enhance or improve mitochondrial function or activity in skin mitochondrial cells, for example, in fibroblasts or senescent fibroblasts.
[0077] Bioactive walnut peptides can be obtained by hydrolysis of walnut protein into small molecule peptides having molecular weights between those of the individual amino acids and those of the protein. This can be carried out using biological or chemical methods. For example, bioactive peptides can be prepared by enzymatic procedures, fermentation, and chemical methods.
[0078] Bioactive walnut peptides can be synthesized by bonding the carboxyl group or C-terminus of one amino acid to the amino group or N-terminus of another amino acid. Protecting groups may be necessary due to the possibility of unintended reactions. Chemical peptide synthesis begins at the C-terminus and ends at the N-terminus of the peptide. Peptides can be synthesized by solid-phase peptide synthesis, liquid-phase peptide synthesis, or fragment condensation. In principle, the seemingly simple formation of peptide bonds can be achieved using all the procedures available in organic chemistry for the synthesis of carboxylic acid amides.
[0079] A common process for synthesizing peptides on a solid phase (e.g., a resin) begins with attaching the first amino acid, the C-terminal residue, to the resin. To prevent polymerization of the amino acid, the alpha-amino group and reactive side chain are protected with a temporary protecting group. Once the amino acid is attached to the resin, the resin is filtered and washed to remove by-products and excess reagents. Next, the N-alpha protecting group is removed in a deprotection process, and the resin is washed again to remove by-products and excess reagents. Then, the next amino acid binds to the attached amino acid. This is followed by another washing procedure, which prepares the resin-peptide for the next binding cycle. This cycle is repeated until the peptide sequence is complete. Typically, all protecting groups are then removed, the peptide resin is washed, and the peptide is cleaved from the resin.
[0080] Enzymatic hydrolysis involves obtaining bioactive peptides using commercially available enzymes. These enzymes cleave peptide bonds established within proteins, thereby releasing the encoded peptides. For an enzyme to exert its activity, it is crucial that it binds to a substrate and continues its enzymatic catalysis. Enzymes have specific active sites, including residues that form transient bonds with the substrate and residues that catalyze the reaction with the substrate. Thus, the binding site and catalytic site are formed, respectively. The bonds forming the enzyme-substrate complex are typically hydrogen bonds, hydrophobic bonds, or van der Waals interactions. Enzymatic hydrolysis can generally be performed in three ways: (i) under conventional batch conditions, (ii) using immobilized enzymes, or (iii) using ultrafiltration membranes. Numerous proteolytic enzymes are known, including, for example, those described in Cruz-Casas et al., Enzymatic Hydrolysis and Microbial Fermentation: The Most Favorable Biotechnological Methods for the Release of Bioactive Peptides (Food Chem (Oxf). 3:100047, Dec. 30, 2021), which is incorporated herein by reference in its entirety.
[0081] Microbial fermentation is a biotechnological process that can yield bioactive peptides. This process involves the use of microorganisms capable of producing proteolytic enzymes, which hydrolyze proteins into shorter peptides. Commonly used microorganisms include bacteria, fungi, or yeasts, which may be naturally present in the substrate or added as inoculum. Microbial fermentation processes can be divided into several systems; however, deep fermentation and solid-state fermentation are the most widely used.
[0082] Deep fermentation uses the cultivation of microorganisms in a liquid medium containing nutrients. This system is suitable for microorganisms with high water activity levels, such as bacteria, and offers the advantage that the resulting bioactive peptides are easily purified. Solid fermentation uses the growth of microorganisms on a nutrient-rich solid substrate. Solid fermentation has the advantage of controlled nutrient release and is suitable for fungi and microorganisms that require less water.
[0083] Biologically active walnut peptides are described in Merrifield, RB, Solid Phase Peptide Synthesis I., J.AM.CHEM.SOC.85:2149-2154 (1963); Carpino, LA et al., [(9-Fluorenylmethyl)oxy]carbonyl (Fmoc)Amino Acid Chlorides: Synthesis, Characterization, And Application To The Rapid Synthesis Of Short Peptides, J.ORG.CHEM.37:51:3732-3734; Merrifield, RB et al., Instrument For Automated Synthesis Of Peptides, ANAL.CHEM.38:1905-1914 (1966); or Kent, SBT et al., High Yield Chemical Synthesis Of Biologically Active Peptides On An Automated Peptide Synthesizer Of Novel Design, IN:Peptides 1984 (Ragnarsson). It can be produced using any method known to those skilled in the art, such as that disclosed in U., ed.) Almqvist and Wiksell Int., Stockholm (Sweden), pp. 185-188.
[0084] The therapeutically effective amount of one or more bioactive walnut peptides varies depending on the bioactive walnut peptides and the combination thereof. However, in various embodiments, the therapeutically effective amount is per 1 cm of skin. 2 The amount can range from approximately 1 μg to approximately 50 mg (50,000 μg) per unit area. In further embodiments, the therapeutically effective amount of one or more walnut peptides per 1 cm² of skin is 2Approximately 1 μg to 40 mg, approximately 1 μg to 30 mg, approximately 1 to 20 mg, approximately 1 μg to 10 mg, approximately 1 μg to 8,000 μg, approximately 1 μg to 5,000 μg, approximately 1 μg to 2,000 μg, approximately 1 μg to 1,000 μg, approximately 10 μg to 40 mg, approximately 10 μg to 30 mg, approximately 10 to 20 mg, approximately 10 μg to 10 mg, approximately 10 μg to 8,000 μg, approximately 10 μg to 5,000 μg, approximately 10 μg to 2,000 μg, approximately 10 μg to 1,000 μg, approximately 100 μg to 50 mg, approximately 100 μg to 40 mg, approximately 100 μg The amounts are approximately 30 mg, 20 mg from approximately 100 μg, 10 mg from approximately 100 μg, 8,000 μg from approximately 100 μg, 5,000 μg from approximately 100 μg, 2,000 μg from approximately 100 μg, 1,000 μg from approximately 100 μg, 50 mg from approximately 500 μg, 40 mg from approximately 500 μg, 30 mg from approximately 500 μg, 30 mg from approximately 500 μg, 20 mg from approximately 500 μg, 10 mg from approximately 500 μg, 8,000 μg from approximately 500 μg, 5,000 μg from approximately 500 μg, 2,000 μg from approximately 500 μg, or 1,000 μg.
[0085] Bioactive walnut peptides are typically formulated with physiologically acceptable carriers and applied to the skin as pharmaceutical and cosmetic compositions. The amount of one or more bioactive walnut peptides varies depending on their activity, use, and interaction with additional bioactive walnut peptides that may be optionally included in the pharmaceutical or cosmetic composition. However, in various embodiments, the pharmaceutical or cosmetic composition contains about 0.01 to about 10% by weight of one or more bioactive walnut peptides, based on the total weight of the pharmaceutical or cosmetic composition.
[0086] In further embodiments, the pharmaceutical or cosmetic composition contains, based on the total weight of the pharmaceutical or cosmetic composition, about 0.01 to about 8% by weight, about 0.01 to about 5% by weight, about 0.01 to about 3% by weight, about 0.01 to about 1% by weight, about 0.01 to about 0.5% by weight, about 0.1 to about 10% by weight, about 0.1 to about 8% by weight, about 0.1 to about 5% by weight, about 0.1 to about 3% by weight, about 0.1 to about 1% by weight, about 0.5 to about 10% by weight, about 0.5 to about 8% by weight, about 0.5 to about 5% by weight, about 0.5 to about 3% by weight, about 0.5 to about 2% by weight, about 1 to about 10% by weight, about 1 to about 8% by weight, about 1 to about 5% by weight, about 1 to about 3% by weight, or about 0.1 to about 2% by weight of one or more bioactive walnut peptides.
[0087] In one embodiment, one or more bioactive peptides and pharmaceutical or cosmetic compositions described throughout this disclosure are useful for improving the tensile properties of the skin, enhancing collagen synthesis, and / or activating the collagen biosynthesis pathway.
[0088] Collagen is produced in many places throughout the body. To date, at least 28 types of collagen have been identified and described, providing the various structural and functional properties that collagen exhibits throughout the body. The five most common types are collagen I, II, III, IV, and V. However, more than 90% of the collagen in the body is type I.
[0089] In human skin, collagen types I and III are the dominant types. They exist as fibrils and are responsible for the stiffness and strength of the dermis. Type I collagen is the dominant collagen in adult human skin and accounts for about 80% of the total collagen volume, playing a major role in providing tensile strength to the skin. However, it has become clear that type III collagen, which accounts for about 10% of the total dermal collagen, also plays an important role in providing further tensile properties to the skin and other tissues.
[0090] Structurally, three collagen polypeptides spirally wrap around each other to form a triple-helical collagen I or III molecule. These molecules are packaged in a five-strand rope-like structure in which each collagen molecule is positioned a quarter length ahead of the next molecule to form a microfibril. Subsequently, the microfibrils wrap around other microfibrils to form fibrils, which then wrap around other fibrils to generate even larger fibrils.
[0091] Previous histological and ultrastructural studies have extensively documented the reduction in both type I and type III collagen synthesis in aged skin. Regarding photoaging, Schwarz et al. (Photochem Photobiol 1993, 58, 841-844) demonstrated that collagen loss in sun-damaged human skin is due to increased degradation of both type I and type III collagen. In addition, fibroblasts derived from sun-exposed skin were shown to synthesize a lower percentage of collagen III than cells derived from sun-protected skin (J Photochem Photobiol B. 1995, 27:33-38).
[0092] Other types of collagen are also present in the skin, and these can change with skin aging. For example, collagen VII, which plays a role in anchoring the basement membrane to the dermal matrix, decreases with age (see Eur J Dermatol 2008;18:297-302). One of the further major morphological features of aging skin is changes in the dermal-epidermal junction, which structurally manifests as flattening of the dermal-epidermal junction contour, accompanied by the disappearance of interpapillary processes and the re-replication of the lamina compacta. Because the dermal-epidermal junction is involved in the aggregation between the dermis and epidermis, age-related changes in the dermal-epidermal junction as a result of the decrease in collagen VII likely lead to functional changes in the skin's resistance to mechanical stress and tissue homeostasis, which is likely to contribute to wrinkle formation.
[0093] Collagen V is thought to assemble into diverse molecular forms and be expressed in the skin as different subtypes, each playing a distinct but important role in the organization and stability of the matrix (see J Invest Dermatol 2012, 132:1841-1849). Collagen V is a defect product in most cases of classical Ehlers-Danlos syndrome, a disorder of extracellular matrix components typically characterized by skin fragility and abnormal wound healing, but it does not appear to change significantly with skin aging.
[0094] In the dermis, which is rich in collagen, further collagen types such as collagen VI, XIV, and XVI are also expressed.
[0095] In vivo collagen production requires transcription in the cell nucleus, polypeptide synthesis via translation from mRNA, organization of polypeptides into a procollagen triple helix in the cytoplasm, and activation of the collagen biosynthesis pathway, which then facilitates cleavage, fibril assembly, and crosslinking extracellularly. Unlike many proteins that are stored in secretory granules and then secreted from cells as needed, collagen is continuously secreted.
[0096] In one embodiment of the present disclosure, one or more bioactive walnut peptides and pharmaceutical or cosmetic compositions containing them are useful for improving skin elasticity, enhancing elastin synthesis, and preventing elastin degradation.
[0097] Elastin is a vital component of the extracellular matrix in vertebrates, providing many tissues and organs, including skin, with excellent properties such as elasticity and tensile strength. Mature elastin is an extremely durable protein that is insoluble and undergoes little turnover; however, sustained exposure to proteases can cause irreversible and severe damage, and thus lead to functional loss of the elastic fiber network. In general, elastin content decreased with age in skin not exposed to sunlight (i.e., buttocks) (i.e., elastin content decreased by approximately 44% between the ages of 50 and 70). A similar decrease was observed in skin with heavy sun exposure (i.e., face) (i.e., elastin content decreased by approximately 31% between the ages of 50 and 70). Interestingly, elastin content in moderately sun-exposed areas (i.e., forearms) did not change significantly with age. This phenomenon can be explained by a combination of age-induced decrease and sun-dependent increase in elastin, which is thought to be at least partially regulated by UV-inducible lysozyme deposition in elastin fibers. (See JEADV, 2006, 20, 980-987).
[0098] Fibrillin (e.g., fibrillin 1) is a ubiquitous glycoprotein of the extracellular matrix, which autopolymerizes into filamentous microfibrils in which individual molecules organize into longitudinal arrays from head to tail and also bind laterally (see Fibrogenesis & Tissue Repair, 2010, 3, 24). In addition, fibrillin microfibrils can act as structural templates for tropoelastin deposition and / or crosslinking during elastic fiber formation. Certain segments of fibrillin interact in vitro with numerous extracellular signaling and cell surface molecules, including fibronectin, fibrin, syndecane, and integrins. The multiple molecular interactions of fibrillin are thought to drive the assembly of morphologically distinct macroaggregates, which contribute to conferring structural integrity to individual tissues and organs (structural role) and directing cellular behavior by targeting TGF-beta and BMP complexes to the architectural matrix (directive role). TGF-beta and BMP are potent modulators of extracellular matrix metabolism, controlled by a complex network of relay and servo mechanisms acting both inside and outside the cell, as well as on the cell surface. Therefore, fibrillin is a crucial component of the extracellular matrix, necessary for the formation of other extracellular matrix components such as elastin and for the formation of elastic fibers.
[0099] In one embodiment of the present disclosure, one or more bioactive peptides and pharmaceutical or cosmetic compositions containing them are useful for increasing hyaluronic acid levels in excess cellular matrix of the skin, for enhancing glycosaminoglycan production, or a combination thereof.
[0100] Hyaluronic acid (also called hyaluronan) is an anionic, non-sulfated glycosaminoglycan. Because hyaluronic acid is not sulfated, it can become very large, and its molecular weight (g mol) is... -1Hyaluronic acid is unique among sugar chain aminoglycans because its molecules often reach millions. As a dominant, large molecule, hyaluronic acid is a major component of the extracellular matrix of skin. Hyaluronic acid provides structure, volume (associated with its excellent water-retaining properties), and organization (for example, by facilitating the transport of ionic solutes and nutrients), but it also contributes significantly to cell proliferation and migration in the dermis. In addition, through its water-retaining properties, hyaluronic acid contributes to skin hydration.
[0101] Glycosaminoglycans (e.g., hyaluronic acid, chondroitin sulfate, heparan sulfate, dermatan sulfate, keratan sulfate, etc.), and hyaluronic acid in particular, are major components of the extracellular matrix of the skin involved in wound healing and tissue regeneration. Wound healing is a dynamic and interactive process involving many precisely correlated phases that overlap in time and lead to the restoration of tissue integrity. The healing process reflects a complex and coordinated bodily response to tissue damage resulting from the interaction of different cell types and extracellular matrix components. Hyaluronic acid plays a crucial role in each phase of wound healing by stimulating cell migration, differentiation, and proliferation, and by regulating the organization and metabolism of the extracellular matrix. Glycosaminoglycans, especially hyaluronic acid, are also involved in skin aging.
[0102] As R. Stern summarized in 2010 (Textbook of Aging Skin, Springer), the dermis of the skin is responsible for most of the hyaluronic acid, but epidermal cells (e.g., keratinocytes) can also synthesize hyaluronic acid. The most dramatic histochemical change observed in aging skin is a significant decrease in epidermal hyaluronic acid. In the skin of older adults, hyaluronic acid is still present in the dermis, while epidermal hyaluronic acid is completely absent. The reason for this rapid decline with age is unknown. It has been described that the synthesis of epidermal hyaluronic acid is influenced by the dermis located beneath it, indicating that epidermal hyaluronic acid is under separate regulation from dermal hyaluronic acid.
[0103] In one embodiment of the present disclosure, one or more bioactive peptides and pharmaceutical or cosmetic compositions containing them are useful for wound healing, minimizing scarring, or a combination thereof.
[0104] In addition to skin aging, collagen I and III are also major extracellular matrix components involved in scar formation. Scarring occurs after trauma, injury, or surgery to any tissue and organ in the body. Such scars are the result of a repair mechanism that replaces missing normal tissue with extracellular matrix, mainly composed of collagen types I and III, along with fibronectin and some other extracellular matrix components. Scarring represents incomplete tissue regeneration. Skin wounds in early mammalian embryos (e.g., up to approximately 24 weeks of gestation in humans) heal completely with the restoration of normal skin structure completed without signs of scarring, but wound healing after birth is accompanied by scarring. (See Dang C et al., Clin Plast Surg 2003:30, 13-23).
[0105] There are phenotypic differences between fetal and postnatal wounds in terms of collagen content and cross-linking patterns (see Clin Plast Surg 2003, 30, 13-23 and Curr Opin Pediatr 2012, 24, 371-378). In fetal wounds, type III collagen rapidly deposits in a fine reticular network indistinguishable from undamaged skin. After birth, the ratio of type I collagen to type III collagen increases within the wound. Of the many different collagen types identified, fetal skin is known to contain a higher proportion of type III collagen, while adult skin is composed mainly of type I collagen. The predominance of type I collagen in postnatal wounds leads to greater strength and stiffness, resulting in greater tissue regeneration. Early scar formation in fetal wounds in late pregnancy shows larger collagen fibers with larger interfibrous spaces.
[0106] In one embodiment of the present disclosure, one or more bioactive peptides and pharmaceutical or cosmetic compositions containing them are useful for preventing, treating, or reversing skin aging and / or signs of skin aging.
[0107] Terms such as "skin aging," "signs of skin aging," and "topical application" are all used in the sense that they are commonly and widely used in the field of the development, testing, and marketing of pharmaceutical, cosmetic, and personal care products, and in reference to pharmaceuticals indicated for skin aging.
[0108] Skin aging is classified into intrinsic and extrinsic aging depending on its cause. Intrinsic aging is the process by which the structure and physiological function of the skin deteriorate as a person ages, regardless of environmental changes. Extrinsic aging is caused by continuous exposure to external environmental factors such as sunlight and air pollutants. Skin aging caused in particular by sunlight is called photoaging. Ultraviolet (UV) light from the sun is the main cause of physiological and morphological changes in aged skin.
[0109] As intrinsic skin aging progresses, the skin dries out, and fine lines and wrinkles form, becoming more visible and deeper with age. Furthermore, due to structural and functional changes in the epidermis and dermis, the skin loses its elasticity and appears to sag. The dermis thins with age, and highly visible skin folds (e.g., nasolabial folds) are formed. It is estimated that adults lose approximately 1% of their total collagen each year. In addition, remaining collagen fibers gradually thicken, and cross-linking of collagen fibers increases, leading to a decrease in their solubility and elasticity. Furthermore, elastin fibers thicken, and their cross-linking also increases. Moreover, the proliferative activity of fibroblasts in the dermis decreases over time, and the ability of aging fibroblasts to form (i.e., synthesize) new collagen, elastin, hyaluronic acid, and other extracellular matrix components also decreases.
[0110] Continuous exposure to sunlight is a major cause of extrinsic skin aging. Typically, the UV components of sunlight, particularly UVA and UVB, are considered the primary causative agents in this process known as photoaging. While the amount of UV exposure required to cause "photoaging" is currently unknown, the amount sufficient to cause erythema (redness commonly described as sunburn) in human skin is quantified as the "minimum erythematous dose" (MED) from a given UV light source. Nevertheless, repeated exposure to levels of sunlight UV that cause erythema and suntan is generally associated with photoaging.
[0111] The physiology of naturally aged (i.e., aged over time) skin differs from that of photoaged skin. Skin aged over time typically maintains a smooth, flawless appearance compared to the leathery, mottled, and often deep wrinkles of photoaged skin. Clinically, photoaging is characterized by roughness, wrinkles, mottled pigmentation, yellowness, flaccidity, tubular dilation, lentigo, purpura, and relatively easy subcutaneous hemorrhage, atrophy, depigmentation, eventually pre-malignant tumors, and ultimately malignant tumors (i.e., abnormal tumors of tissue resulting from neoplastic formation, which is abnormal cell proliferation). Photoaging commonly occurs on skin normally exposed to sunlight, such as the face, ears, areas of hair loss on the scalp, neck, décolleté, forearms, and hands.
[0112] While the typical appearance of photoaged and aged human skin is easily distinguishable, recent evidence indicates that aged skin and UV-irradiated skin share important molecular characteristics. This suggests that they promote the expression of matrix-metalloproteinases (e.g., collagenase, gelatinase), leading to the degradation of the extracellular matrix, decreased collagen formation, and alteration or damage to the extracellular matrix of the skin, such as the accumulation of amorphous elastin-containing material beneath the epidermal-dermal junction. This correspondence in molecular mechanisms suggests that UV irradiation accelerates many important aspects of the aging process in human skin.
[0113] "Signs of skin aging" include, but are not limited to, all manifestations that are externally perceptible visually and tactilely, as well as any other macroscopic or microscopic effects resulting from skin aging. Such signs may be triggered or caused by intrinsic factors (presented as skin aging over time) and extrinsic factors (presented as environmental skin damage, including but not limited to photoaged skin). These signs may result from processes including, but are not limited to, the development of tissue discontinuities such as wrinkles and deep creases, fine lines or skin lines, fissures, elevations, large pores (e.g., associated with appendage structures such as sweat ducts, sebaceous glands), or unevenness or roughness, loss of skin elasticity (loss and / or inactivation of functional cutaneous elastin), sagging (including swelling around the eyes and chin), loss of skin firmness, loss of skin tightness, loss of skin recovery from deformation, discoloration (including dark circles under the eyes), pigmented skin areas such as spots, yellowing, senile lentigines and freckles, keratinization, abnormal differentiation, hyperkeratosis, increased elastic fibers, collagen breakdown, and other histological changes in the stratum corneum, dermis, epidermis, cutaneous vascular system (e.g., capillary dilation or arachnoid vessels), and underlying tissues, particularly tissues close to the skin.
[0114] In various embodiments of this disclosure, one or more bioactive peptides, and pharmaceutical or cosmetic compositions comprising them, are useful for preventively preventing, treating, or regulating skin conditions. As used herein, preventively preventing, treating, or regulating skin conditions includes delaying, minimizing, and / or preventing visual and / or tactile discontinuities of the skin, including signs of skin aging (e.g., irregularities in skin texture that can be detected visually or by touch). This also includes improving, for example, reducing, minimizing, and / or eliminating discontinuities of the skin, including signs of skin aging.
[0115] Pharmaceutical and cosmetic compositions containing one or more bioactive walnut compositions can be formulated in various forms, such as lotions, creams, serums, sprays, emulsions, gels, powders, dispersions, ointments, sticks, pastes, and foams. In addition to physiologically acceptable carriers, pharmaceutical and cosmetic compositions may optionally contain one or more of the following: • Ascorbate and other vitamins, • Sunscreen surfactants, • Anti-wrinkle activators and anti-atrophy activators, • Humectants, moisturizers, conditioning agents, • Skin softeners, • Antioxidants and free radical scavengers, • Exfoliating agents, epidermal exfoliants, and exfoliating agents • Suspensions, ·emulsifier, • Thickening agents and / or • Antihistamine.
[0116] Ascorbate and other vitamins The pharmaceutical or cosmetic compositions of this disclosure may include one or more vitamins, such as ascorbates (e.g., vitamin C, vitamin C derivatives, ascorbic acid, ascorbyl glucoside, ascorbyl palmitate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, tetrahexadecyl scorbate, ascorbyl phosphate, aminopin-3-aminopinamine) B, derivatives of vitamin B, vitamins B1-B12 and their derivatives, vitamin K, derivatives of vitamin K, vitamin H, vitamin D, vitamin D3, derivatives of vitamin D, vitamin E, derivatives of vitamin E and its provitamins, such as nethole, and mixtures thereof. Vitamin compounds may be included as substantially pure materials or as extracts obtained by appropriate physical and / or chemical isolation from natural (e.g., plant) sources.
[0117] The amount of one or more vitamin compounds in a pharmaceutical or cosmetic composition varies, but is typically about 0.0001% to about 25%, more preferably about 0.001% to about 10%, more preferably about 0.01% to about 5%, and more preferably about 0.1% to about 1%, based on the total weight of the pharmaceutical or cosmetic composition.
[0118] Sunscreen surfactant The pharmaceutical and cosmetic compositions of this disclosure may optionally include sunscreen activators, which may also be called UV filtering agents. As used herein, “sunscreen activator” includes both UV reflectors and physical sunscreens. Suitable sunscreen activators may be organic or inorganic. A wide variety of standard organic or inorganic sunscreen activators are suitable for use according to the present invention.
[0119] The amount of one or more sunscreen activators in a pharmaceutical or cosmetic composition varies. However, in some embodiments, the pharmaceutical or cosmetic composition contains sunscreen activators in amounts ranging from about 0.1% to about 25%, and more commonly from about 0.5% to about 10%, based on the total weight of the pharmaceutical or cosmetic composition.
[0120] Non-exclusive examples of organic sunscreen surfactants include ethylhexyl salicylate, butyl methoxybenzoylmethane, ethylhexyl methoxy cinnamate, octocrylene, phenylbenzimidazole sulfonic acid, terefsalilidene dicamphor sulfonic acid, benzophenone-4-benzophenone-3 camphormethylbenzylidene, benzimidazilate, anisotriazine, ethylhexyl triazone, diethylhexyl butamide triazone, methylene-bis-benzotriazolyltetramethylbutylphenol, drometrazol trisiloxane, and mixtures thereof.
[0121] Non-limiting examples of inorganic sunscreens include nanopigments (average primary particle size: generally between 5 nm and 100 nm, preferably between 10 nm and 50 nm), or aggregates coated or uncoated with metal oxides, such as titanium dioxide nanopigments (amorphous or crystalline in the form of rutile and / or anatase), iron, zinc, zirconium or cerium oxides, and mixtures thereof. Coating agents also include alumina and / or aluminum stearate and silicones.
[0122] Anti-wrinkle activator and anti-atrophy activator The pharmaceutical or cosmetic compositions of this disclosure may optionally contain one or more anti-wrinkle or anti-atrophy agents. Non-limiting examples of anti-wrinkle and anti-atrophy agents include proxylene, amino acids, N-acetyl derivatives of amino acids (e.g., N-acetylcysteine), hydroxy acids (e.g., alpha hydroxy acids, e.g., lactic acid and glycolic acid, or beta hydroxy acids, e.g., salicylic acid and salicylic acid derivatives, e.g., octanoyl derivatives, lactobionic acid), keto acids (e.g., pyruvate), and fiti hydrochloric acid. Ascorbic acid (vitamin C), retinoids (e.g., retinoic acid, tretinoin, isotretinoin, adapalene, retinol, retinyl aldehyde, retinyl palmitate and other retinoid derivatives), kinetin (N6-furfuryl adenine), zeatin, and their derivatives, e.g., furynifenyrenyrenyrnidirophenide, niacinamide (nicotinamide); growth factors and cytokines Ingredients (e.g., TGF-beta 1, 2 and 3, ERF, FRF-2, TGF, IL-1, IL-6, IL-8, IGF-1, IGF-2, etc.), cell lysates (e.g., dermal fibroblast lysates, stem cell lysates, processed skin cell proteins (PSP®, etc.)), conditioning media (e.g., conditioning media derived from dermal fibroblasts, conditioning media derived from stem cells (e.g., epidermal stem cells, adipose tissue stem cells, mesenchymal stem cells, etc.); trademarks Nouricel-MD®, TNS®, or CCMTM Cosmetics sold under the name Complex, etc.; cell extracts, stem cell extracts, stem cell components; ingredients that stimulate epidermal stem cells or adult stem cells; skin conditioning agents, stilbene, cinnamate, sirtuin-1 activators (e.g., resveratrol); mitochondrial function activators; dimethylaminoethanol, synthetic anti-aging peptides, naturally derived peptides (e.g., soy peptides) and sugar salts (e.g., Mn gluconate, Zn gluconate), lipoic acid; lysophosphatidyl acid, vitamin B3 compounds and other vitamin B compounds (e.g., thiamine (vitamin B1), pantothenic acid (vitamin B5), riboflavin (vitamin B2) and their derivatives and salts (e.g., HCl salts or calcium)).
[0123] The total amount of anti-wrinkle and / or anti-atrophy agents in a pharmaceutical or cosmetic composition varies. However, in some embodiments, the pharmaceutical or cosmetic composition contains one or more anti-wrinkle and / or anti-atrophy agents in an amount of about 0.0001% to about 10% by weight, more preferably about 0.001% to about 8% by weight, more preferably about 0.01% to about 5% by weight, and more preferably about 0.1% to about 1% by weight, based on the total weight of the composition.
[0124] Humectants, moisturizers, and conditioning agents The pharmaceutical or cosmetic composition of the present invention may optionally contain an effective amount of a humectant, moisturizer, and / or skin conditioning agent. If one or more humectants, moisturizers, and conditioning agents are present, their total amounts will vary. However, in some embodiments, the pharmaceutical or cosmetic composition contains one or more humectants, moisturizers, and / or conditioning agents in an amount of about 0.01% to about 80% by weight, more preferably about 0.1% to about 25% by weight, and more preferably about 0.5% to about 10% by weight, based on the total weight of the pharmaceutical or cosmetic composition.
[0125] Humectants are ingredients that help maintain the skin's moisture level. Non-limiting examples of humectants include polyhydric alcohols, water-soluble alkoxylated nonionic polymers, and mixtures thereof. Non-limiting examples of polyols include the polyhydroxy alcohols mentioned above, as well as glycerol, hexylene glycol, ethoxylated glucose, 1,2-hexanediol, dipropylene glycol, trehalose, diglycerin, maltitol, maltose, glucose, fructose, sodium chondrophosphate gum sodium nitrophosphate, sodium lactate, pyrrolidone carbonate, glucosamine, cyclodextrin, and mixtures thereof. Water-soluble alkoxylated nonionic polymers useful for this application include polyethylene glycol and polypropylene glycol, with molecular weights up to approximately 1000, such as polyethylene glycol and polypropylene glycol named by the Association for Perfumes and Cosmetics and Fragrances (CTFA) as PEG-200, PEG-400, PEG-600, PEG-1000, and mixtures thereof. Additional humectants include acetylarginine, algal extracts, aloe barbaden leaf extract, 2,3-butanediol, chitosan lauroyl glycinate, diglyceride-7 malate, diglycerol, diglycol guazinine succinate, erythritol, fructose, glucose glycosyl hydrochloride, glycosyl hydrochloride, glycosyl hydrochloride, glycosyl hydrochloride, glycosyl hydrochloride, inositol, lactitol, maltitol, maltose, mannitol, mannose, methoxypolyethylene glycol, myristamide butylguazinine acetate, polyglyceryl sorbitol, potassium pyrrolidone carboxylic acid (PCA), propylene glycol, butylene glycol, atriapyrrolidone carboxylic acid (PCA), sorbitol, sucrose, and dextran.
[0126] Non-exclusive examples of conditioning agents include guazinine, urea, glycolic acid, glycolates (e.g., ammonium and tetraalkylammonium), salicylic acid, lactic acid, lactates (e.g., ammonium and tetraalkylammonium), aloe vera and any of its various forms (e.g., aloe vera gel), polyhydroxy alcohols such as sorbitol, mannitol, xylitol, erythritol, hexanetriol, butanetriol, propylene glycol, butylene glycol, hexylene glycol, etc., polyethylene glycol, propoxylated glycemic substitutes, sugars (e.g., melibiose), starch, sugars and starch derivatives (e.g., alkoxylated glucose, fructose, glucosamine), and C1-C sugars. 30 This includes monoesters and polyesters and related substances, hyaluronic acid, lactamide monoethanolamine, acetamide monoanthenol, acetamide monoanthenol allantoin, and mixtures thereof. Skin conditioning agents may also include fatty acids, fatty acid esters, lipids, ceramides, cholesterol, cholesterol esters, beeswax, petrolatum jelly, and mineral oil.
[0127] Skin softener One or more emollients may also be optionally included in the pharmaceutical or cosmetic compositions described herein. Generally, emollients refer to ingredients that can help maintain the appearance of soft, smooth, and supple skin. Generally, emollients remain on the surface of the skin or within the stratum corneum, acting as moisturizers or lubricants and reducing delamination. Non-exclusive examples of emollients include acetylarginine, acetylated lanolin, algal extracts, polyethylene glycol-6 ester derived from apricot kernel oil, polyethylene glycol-11 ester derived from avocado oil, bis-polyethylene glycol-4 dimethicone, butoxyethyl stearate, glycol esters, alkyl glycol ether esters, cetyl laurate, coconut polyethylene glycol-10 ester, alkyl tartrate, diethyl sebacate, dihydrocholesteryl butyrate, dimethiconol, dimyristyl tartrate, diasterare-5 lauroyl utamato, etilabocadato, ethylhexyl myristate, glyceryl isostearate, glyceryl oleate, glycyl decyl stearate, glycyl isostearate, hydrogenated palm glyceride, and hydrogenated soy glyceride. It contains hydrogenated glycerides of fat isostearyl neopentanoate, isostearyl palmitate, isotridecyl isonanoate, laureth-2 acetate, lauryl polyglyceryl-6 cetearyl glycol ether, methylglutzet-20 benzoate, mineral oil, palm oil, coconut oil, millet-3 palmitate, octyldecanol, octyldodecanol, Odontella aurita oil, 2-oleamide-1,3 octadecanediol, pal commercial glycerides, polyethylene glycol avocado glycerides, polyethylene glycol castor oil, polyethylene glycol-2 / dodecyl glycol copolymer, polyethylene glycol shea butter glycerides, phytol, raffinose, stearyl citrate, sunflower oil glycerides, non-ointment, and small tocopheryl glucoside.
[0128] Antioxidants and free radical scavengers The pharmaceutical and cosmetic compositions of the present invention may optionally contain one or more antioxidants and / or free radical scavengers. For example, the composition may contain one or more antioxidants and / or free radical scavengers in an amount of about 0.001 percent to about 10 percent, more preferably about 0.01 percent to about 8 percent, and more preferably about 0.1 percent to about 5 percent, based on the total weight of the composition.
[0129] Non-exclusive examples of antioxidants and free radical scavengers include falcata bark extract, ascorbic acid (vitamin C) and its salts, fatty acid ascorbyl esters and other derivatives of ascorbic acid (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate, ascorbyl tetrabeprite, tetraascorbyl tetraval and ascorbyl tetraxald, etc.), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other tocopherol esters, beta-carotene, butylated hydroxybenzoic acid and its salts, ferulic acid, peroxides including hydrogen peroxide, perborates, thioglycolates, persulfates, and 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (trademark name Trolox). TM(Commercially available) gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, amines (e.g., N,N-diethylhydroxylamine, aminoguazinine), nordihydroguaiaretic acid, bioflavonoids, sulfhydryl compounds (e.g., glutathione), dihydroxyfumarate and its salts, lysine lignin phenolate simarin, lysine, 1-methionine, proline, superoxide dismutase, sorbic acid and its salts, lipoic acid, olive extract, tea extract, resferatrol, po Polyphenol-containing plant extracts include, but are not limited to, coffee bean extract, green tea extract, rosemary extract, witch hazel extract, and grape skin / seed extract. Preferred free radical antioxidants / scavengers may be selected from ascorbic acid esters, tocopherol, ferulic acid, polyphenols, creatine and its derivatives, and polyphenol-containing plant extracts such as green tea extract.
[0130] Suspension The pharmaceutical and cosmetic compositions of the present invention may optionally contain one or more suspending agents, preferably in a dispersed form within the composition, at concentrations effective for suspending water-insoluble materials or for altering the viscosity of the composition. Such concentrations will vary. However, in some embodiments, the pharmaceutical and cosmetic compositions contain one or more suspending agents in an amount of about 0.1% to about 10%, more preferably about 0.25% to about 5.0%, based on the total weight of the composition. Non-limiting examples include vinyl polymers, such as cross-linked acrylic polymers called carbomers; cellulose derivatives and modified cellulose polymers, such as methylcellulose, ethylcellulose, nitrocellulose, carboxymethylcellulose, crystalline cellulose, cellulose powder, polyvinylpyrrolidone, polyvinyl alcohol, guar gum, hydroxypropyl guar gum, acacia gum, galactan, locust bean gum, pectin, agar, starch (rice, corn, potato, wheat), algal colloids (algae extracts); microbial polymers, such as dextran, succinoglycan, pullulan; starch-based polymers, such as carboxymethyl starch, methyl starch; alginate polymers, such as sodium alginate, propylene glycol alginate; acrylate polymers, such as sodium polyacrylate, polyacrylate, polyacrylamide; polyethyleneimine; and inorganic minute water-soluble materials, such as bentonite, aluminum magnesium silicate, laponite, hectonite, and anhydrous silicic acid.
[0131] Other optional suspensions include crystalline suspensions that can decompose into acyl derivatives, long-chain amino acids, long-chain acyl derivatives, and mixtures thereof. The preferred suspensions include fatty acid ethylene glycol esters, fatty acid alkanolamides, long-chain fatty acid esters (e.g., stearyl stearate, cetyl palmitate, etc.); long-chain esters of long-chain alkanolamides (e.g., stearamide distearate, stearamide monoethanolamide); and glyceryl esters (e.g., glyceryl distearate, trihydroxystearin, tribhengen). Other suitable suspensions include primary amines containing an aliphatic alkyl fragment having at least about 16 carbon atoms (examples include palmitamine or stearamine) and secondary amines containing two fatty alkyl fragments, each having at least about 12 carbon atoms (examples include dipalmitoylamine or di(hydrogenated fatty)amine). Other suitable suspensions include phthalic acid diamide (hydrogenated fat) and crosslinked maleic anhydride / methyl vinyl ether copolymer.
[0132] emulsifier Non-limiting examples of emulsifiers include condensation products of alkylene oxides and fatty acids (i.e., alkylene oxide fatty acid esters), condensation products of alkylene oxides and 2 moles of fatty acids (i.e., fatty acid alkylene oxide diesters), condensation products of alkylene oxides and fatty alcohols (i.e., fatty alcohol alkylene oxide esters), and condensation products of alkylene oxides and both fatty acids and fatty alcohols [i.e., a portion of the polyalkylene oxide is esterified with a fatty acid at one end and esterified with a fatty alcohol at the other end (i.e., via an ether linkage)]. Non-limiting examples of nonionic surfactants obtained from the alkylene oxides include: cetet-6, cetet-10, cetet-12, cetetaret-6, cetetaret-10, cetetaret-12, stearet-6, stearet-10, stearet-12, stearet-21, PEG-6 stearate, PEG-10 stearate, PEG-100 stearate, PEG-12 stearate, PEG-20 glyceryl stearate, PEG-80 glyceryl tallowate, PEG-10 glyceryl stearate, PEG-30 glyceryl cocoate, and PEG-80 glyceryl cocoate. This includes cocoa, PEG-200 glyceryl tauroate, PEG-8 dilaurate, PEG-10 distearate, and mixtures thereof. Other applicable nonionic surfactants include polyhydroxyamide fatty acid surfactants. Particularly preferred surfactants corresponding to the above structures are N-methyl glucoside coconut alkylamides. Among nonionic surfactants, preferred are surfactants selected from the group consisting of steareth-21, steareth-20, steareth-12, sucrose cocoate, steareth-100, PEG-100 stearate, and mixtures thereof.Other nonionic surfactants suitable for use in this application include sugar esters and polyesters, alkoxylated sugar esters and polyesters, C1-C30 fatty acid esters, C1-C30 fatty alcohols, alkoxylated C1-C30 ester derivatives, C1-C30 fatty alcohol fatty acids, alkoxylated C1-C30 fatty alcohol esters, polyglyceryl C1-C30 fatty acid esters, C1-C30 polyol esters, C1-C30 polyol esters, alkyl phosphates, polyoxyalkylene fatty ether forfates, fatty acid amides, acylactylates, and mixtures thereof. Non-limiting examples of these emulsifiers include polyethylene glycol 20 sorbitan monolaurate (polysorbate 20), polyethylene glycol 5 soysterol, stearet-20, cetearet-20, PPG-2 methyl glucose ether distearate, ceteto-10, polysorbate 80, cetyl phosphate, cetyl phosphate, cetyl phosphate, cetyl phosphate, cetyl phosphate, polysorbate 60, glyceryl stearate, polyoxyethylene 20 sorbitan triolcate (polysorbate 80), sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, PPG-2 methyl glucose ether distearate, PEG-100, and their respective PEG-100s. Another group of nonionic surfactants useful herein are mixtures of fatty acid esters based on a mixture of sorbitan or sorbitol fatty acid esters and sucrose fatty acid esters, wherein the fatty acids in each example are preferably C8-C24, more preferably C10-C20 fatty acids.
[0133] Thickening agent Thickeners suitable for inclusion in the pharmaceutical or cosmetic compositions described herein. Non-limiting examples include acrylamide copolymers, agarose, amylopectin, bentonite, calcium alginate, calcium carboxymethylcellulose, carbomer, carboxymethyl chitin, cellulose gum, dextrin, gelatin, hydrogenated hydroxymethyl hydroxycellulose hydroxypropyl, hydroxyethyl hydroxypropyl hydroxypropyl, hydroxyethyl hydroxypropyl, hydroxyethyl hydroxypropyl, hydroxyethyl hydroxypropyl, hydroxyethyl hydroxypropyl, hydroxypropyl, hydroxypropyl, hydroxypropyl, hydroxypropyl; magnesium alginate, methylcellulose, microcrystalline cellulose, pectin, various polyethylene glycols, polyacrylic acid, polymethacrylic acid, polyvinyl alcohol, various sexes ipropylene glycols, copolymers of sodium acrylate, sodium carrageenan, xanthan gum and / or yeast beta-glucan, or mixtures thereof.
[0134] More generally, carboxylic acid polymers are useful thickeners. Carboxylic acid polymers are crosslinked compounds comprising one or more monomers obtained from acrylic acid, substituted acrylic acid, and salts and esters of said acrylic acid and substituted acrylic acid, wherein the crosslinking agent contains two or more carbon-carbon double bonds and is derived from a polyhydric alcohol. Examples of commercially available carboxylic acid polymers useful herein include carbomers, which are homopolymers of acrylic acid crosslinked with sucrose or pentaerythritol allyl ether. Carbomers are available as BFGoodrich's Carbopol® 900 series (e.g., Carbopol® 954). In addition, other suitable carboxylic acid polymer agents include copolymers of C10-30 alkyl acrylates with one or more monomers of acrylic acid, methacrylic acid, or esters of one of their short chains (i.e., C1-4 alcohols), where the crosslinking agent is sucrose or pentaerythritol allyl ether. These copolymers are known as acrylate / C10-30 alkyl acrylate crosspolymers and are commercially available as BFCarbopol® 1342, Carbopol® 1382, Pemulen TR-1 and Pemulen TR-2.Goodrich. Examples of preferred carboxylic acid polymer-based thickeners useful for this application include thickeners selected from carbomers, acrylate / C10-30 alkyl acrylate crosspolymers, and mixtures thereof.
[0135] Furthermore, according to some embodiments, the thickener is selected from polysaccharides. Non-limiting examples of polysaccharide thickeners include cellulose, carboxymethyl hydroxyethyl cellulose, cellulose acetate propionate carboxylate, hydroxyethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium methyl hydroxyethyl cellulose, and hydroxyethyl methyl hydroxyethyl hydroxyethyl cellulose hydroxyethyl methyl hydroxyethyl hydroxyethyl cellulose hydroxyethyl hydroxyethyl cellulose hydroxyethyl hydroxyethyl cellulose hydroxyethyl methyl hydroxyethyl hydroxyethyl. Alkyl-substituted celluloses are also useful. In these polymers, the hydroxyl groups of the cellulose polymer are hydroxylated (preferably hydroxyethylated or hydroxypropylated) to form hydroxylated cellulose. The hydroxylated cellulose is then further modified with C10-30 linear or branched alkyl groups via ether linkages. Typically, these polymers are linear or branched esters of C10-30 alcohols and hydroxyalkyl cellulose. Examples of alkyl groups applicable to this application include groups selected from stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (e.g., alkyl groups obtained from coconut oil alcohol), palmityl, oleyl, linoleyl, linolenyl, resinoleyl, behenyl, and mixtures thereof. A preferred alkylhydroxyalkylcellulose ester is a material called cetylhydroxyethylcellulose, which, according to the Perfume and Cosmetics and Perfume Association (CTFA), is an ester of cetyl alcohol and hydroxyethylcellulose. The material shown is sold by Aqualon Corporation (Wilmington, Delaware) under the trademark name Natrosol® CS Plus.Further examples can be found in The International Cosmetic Ingredient Dictionary and Handbook, the Cosmetic Bench Reference-Directory of Cosmetic Ingredients, and other references to cosmetic and pharmaceutical ingredients known in the art, provided by the United States Pharmacopeia (USP) and National Formulary (NF). Other useful polysaccharides include scleroglucan, which is a linear (1-3) linked glucose unit (1-6), with glucose units linked in groups of three. A commercially available example is Clearogel from Michel Mercier Products Inc. (Mountainside, New Jersey). TM It's CS11.
[0136] Other useful thickeners include those derived from natural sources. Non-limiting examples include gum arabic, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum hydrochloride, gidrohydrochloride, hyaluronic acid hydrochloride, hydrated silicon dioxide, hydroxypropyl chitosan, hydroxypropyl gum, karaya gum, kelp, fruit tree resins, natto gum, potassium alginate, potassium carrageenan (potassium carr gene), propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, dextran, sodium carrageenan, tragacanth gum, xanthan gum, and / or mixtures thereof.
[0137] In addition, the composition may optionally include polyacrylamide polymers, particularly nonionic polyacrylamide polymers including substituted branched or unbranched polymers. Other polyacrylamide polymers useful herein include acrylamide and multiblock copolymers of substituted acrylamides with acrylic acid and substituted acrylic acid.
[0138] antihistamine Antihistamines, also known as histamine antagonists, are substances that inhibit the action of histamine by blocking the attachment of histamine to histamine receptors or by inhibiting the enzymatic activity of histidine decarboxylase, which catalyzes the conversion of histamine and other substances into histamine. Non-specific examples of antihistamines include acribastine, azelastine, brompheniramine, buclidine, bromodifenhydramine, carbinoxamine, cetirizine, chlorpromazine, cyclizine, chlorpheniramine, chlorodiphenhydramine, cimetidine, clemastine, cyproheptadine, desloratine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine dimendenine These are dimenhydramin, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimendenine, dimenhydramine, ebastine), embramin, famotidine, fexofenadine, lafutidine, levocetirizine, lalotadine, meclozine, mirtazapine, nizatidine, olopadadine, orphenadrine, phenindamine, pheniramine, phenyltroxamine, promethazine, pyriramine, quetiapine, ranitidine, roxatidine, rupatadine, triperenamine, and triprolidine.
[0139] Skin activators Non-exclusive examples of dermatoactive agents include rosacea inhibitors (e.g., metronidazole, sulfacetamide, sodium sulfacetamide, sulfur, dapsone, doxycycline, minocycline, clindamycin, clindamycin phosphate, erythromycin, tetracycline, azelaic acid, calcium dobesylate, maleic acid, and any compatible combination thereof); α-adrenergic receptor agonists (e.g., clonidine, amphetamine, doxtroamphetamine, apraclonidine, dipivefrin, α-methyldopa, oxymetazoline, meximetazoline hydrochloride, methoxamine, metalaminol, medetomidine, dexmedetomidine, ethylnorepinephrine, guanfacine, guanabenz, phenylephrine, phenylephrine hydrochloride, ephedrine, epinin, epinephrine, eti Lunorepinephrine, revalterenol, lofexidine, norepinephrine, norphenylephrine, norephedrine, phenylpropanolamine, pemoline, propylhexadrine, pseudoephedrine, methamphetamine, α-methylnorepinephrine, methylphenidate, mephentermine, midodrine, mibazerol, moxonidine, desglimidodrine, tetrahydrozoline, tetrahydrozoline hydrochloride, silazolin, amidephrine, brimonidine, brimonidine tartrate, naphazoline, isoproterenol, xylazine, xylometazoline, and / or tizanidine); corticosteroids, ephedrine, pseudoephedrine, caffeine, and / or escin, including but not limited to these, vasoconstrictive chemicals and plant extracts; ephedra, phedra It contains ingredients such as Hamamelis sinica, Hamamelis viginiana, Hydratis canadensis, Lycopus virginicus, Aspidosperma quebraco, Broom, Radish (radish leaf extract), and Horse chestnut extract.
[0140] In preferred embodiments, the epidermal surfactant is selected from ceramide, ceramide precursor, Melacil® (N-[(1,2-dihydro-2-thioxo-3-pyridinyl)carbonyl]glycine; INCI:2-mercaptonictinoylglycine), free fatty acids, linoleic acid / oleic acid, cholesterol, cholesterol sulfate, β-glucan, carob seed extract, Epel afalcata extract, amino acids, niacinamide and its derivatives, hyaluronic acid and its derivatives, glycerin, allantoin, squalane, omega fatty acids, or combinations thereof.
[0141] Further non-limiting examples include chemicals or plant extracts with anti-inflammatory properties (e.g., corticosteroids (for short-term use)), nonsteroidal anti-inflammatory drugs, linoleic acid, linolenic acid, bisabolol, glycylretinic acid, glycerin, plant extracts with anti-inflammatory properties (i.e., tea extracts, chamomile extracts), anti-inflammatory interleukins (e.g., Il-1ra); isoprenylcysteine analogs (i.e., N-acetyl-S-farnesyl-L-cysteine); aromatic aldehydes with anti-inflammatory properties (e.g., 4-ethoxybenzaldehyde), and any compatible combination thereof); chemicals or plant extracts; chemicals or plant extracts with antimicrobial properties (e.g., gentamicin, penicillin, cephalosporins, quinolones, ciprofloxacin, and / or novobiocin, but these include This includes antibiotics (not limited to those listed above); chemicals or plant extracts having antifungal properties (e.g., ketoconazole, naphthifine hydrochloride, oxiconazole nitrate, sulconazole nitrate, urea, terbinafine hydrochloride, selenium sulfate, etc.); chemicals or plant extracts having anti-dandruff properties; chemicals or plant extracts having anti-seborrheic properties; keratolytic agents or plant extracts having epidermal exfoliating properties (i.e., alpha-hydroxy acids; beta-hydroxy acids, poly-hydroxy acids, urea, salicylic acid, etc.); chemicals having astringent properties; serine protease inhibitors; saturated dicarboxylic acids; alpha-hydroxy acids (e.g., glycolic acid, lactic acid, malic acid, citric acid, tartaric acid, etc.); and beta-hydroxy acids (e.g., carnitine, 3-hydroxybutyric acid, 3-hydroxypropionic acid, β-hydroxyβ-methylbutyric acid, salicylic acid, etc.).
[0142] Further non-exclusive examples of dermatotropic agents include retinoic acid, tretinoin, isotretinoin, adapalene, retinol, and / or derivatives; benzoyl peroxide; dapsone; kinetin (N6-furfuryladenine) and derivatives (e.g., furfurylaminotetrahydropyranyladenine); niacinamide (nicotinamide), and combinations thereof.
[0143] Further non-limiting examples of skin surfactants include metronidazole, sulfacetamide, sodium sulfacetamide, sulfur, tetracycline, doxycycline, clindamycin, clindamycin phosphate, erythromycin, and / or minocycline, azelaic acid, calcium dobesylate, caffeine, theobromine, theophylline and / or derivatives thereof (i.e., xanthine), vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B5, vitamin B6, vitamin B7, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E and vitamin K, This includes, but is not limited to, rheatin, carnitine, and essential fatty acids such as linoleic acid and / or linolenic acid, zinc salts such as zinc sulfate, zinc chloride, zinc glycinate, zinc gluconate, zinc histidine, zinc L-2-pyrrolidone-5-carboxylate (zinc PCA), zinc salts of linoleic acid, zinc salts of linolenic acid, zinc salts of azelaic acid, zinc peptides, zinc oxide, and copper salts, including, but not limited to, copper sulfate, copper chloride, copper glycinate, copper gluconate, copper histidine, copper L-2-pyrrolidone-5-carboxylate (copper PCA), copper salts of linoleic acid, copper salts of linolenic acid, copper salts of azelaic acid, and copper peptides.
[0144] Non-exclusive examples of skin surfactants include madecassoside, retinoic acid, benzoyl peroxide, sulfur, vitamin B6 (pyridoxine or) chloride, selenium, samphire, cinnamon extract blend, zinc gluconate, zinc pyrrolidone carboxylate (or zinc pyrdolate), zinc lactate, zinc aspartate, zinc carboxylate, zinc salicylate, zinc cysteine, copper as Cuivridone Solabia and copper pyrdolate, Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis, Salvia officinalis This includes plant-derived extracts of *Thymus officinalis* and *Thymus vulgaris*, extracts of *Spiraea ulmaria*, and mixtures thereof.
[0145] In various embodiments, one or more skin surfactants may include adenosine, 2-[4-(2-hydroxyethyl)piperazine-1-yl]ethanesulfonic acid (HEPES), hyaluronic acid, lanolin, citric acid, malic acid, lactic acid, tartaric acid, salicylic acid, vitamin C, vitamins, retinoids, retinal, retinoic acid, carotenoids, amino acids, proteins, enzymes, and coenzymes. In some cases, the active ingredient is adenosine.
[0146] In one embodiment, the composition comprises one or more skin activators selected from humectants and moisturizing agents, depigmentants, or agents for treating oily skin.
[0147] Moisturizers and wetting ingredients include, in particular, glycerol and its derivatives, urea and its derivatives, Hydrovance, lactic acid, hyaluronic acid, AHA, BHA, sodium pyrophosphate, xylitol, serine, sodium lactate, ectoin and its derivatives, chitosan and its derivatives, collagen, plankton, Imperata cylindra extract, sold by Sederma under the name Moist 24, acrylic acid homopolymer as Lipidure-HM from NOF Corporation, beta-glucan and, in particular, sodium carboxymethyl beta-glucan from Mibelle-AG-Biochemistry, passionflower oil, apricot, corn, and rice bran mixtures, sold by Nestle under the name NutraLipids, C-glycoside derivatives, in particular the trademark name "Mexoryl Products manufactured by Chimex under the name "SBB" may include C-13-D-xylopyranoside-2-hydroxypropane in the form of a solution of 30% by weight of the active material in a water / propylene glycol mixture (60 / 40% by weight), rosehip oil marketed by Nestle, zinc-enriched microalgae extract marketed by Vincience under the name Algualane Zinc, marine-derived collagen and chondroitin sulfate spheres (Atelocollagen) marketed by Engelhard Lyon under the name Marine Filling Spheres, hyaluronic acid spheres, for example, marketed by Engelhard Lyon, and arginine.
[0148] Decolorizing agents include vitamin C and its derivatives, and in particular vitamin CG, CP and 3-O-ethyl vitamin C, alpha and beta arbutin, ferulic acid, lucinol and its derivatives, kojic acid, resorcinol and its derivatives, tranexamic acid and its derivatives, gentisic acid, homogentisic acid, methyl gentisate or homogentisic acid, diacitic acid, calcium D-pantetheine sulfonate, lipoic acid, ellagic acid, vitamin B3, linoleic acid and its derivatives. This list includes derivatives, Melasyl® (N-[(1,2-dihydro-2-thioxo-3-pyridinyl)carbonyl]glycine; INCI: 2-mercaptonicotinoylglycine), ceramides and their counterparts derived from plants such as chamomile, bearberry, aloe (Aloe vera, Aloe ferox, Aloe barbadensis), mulberry, sedge, kiwi fruit water (kiwi fruit water) marketed by Gattefosse, peony root extract, for example, sold by Ichimaru Pharcos under the name Liquid Botanpi Be, and brown sugar (sugarcane) extract, for example, honey extract marketed by Taiyo Kagaku under the name Liquid Molasses, but this list is not exhaustive. Certain decolorizing agents include vitamin C and its derivatives, as well as vitamin CG, CP and 3-O-ethyl vitamin C, alpha and beta arbutin, ferulic acid, kojic acid, resorcinol and its derivatives, calcium D-pantetheine sulfonate, lipoic acid, ellagic acid, vitamin B3, kiwi fruit water (kiwi fruit water) marketed by Gattefosse, and peony root extract, for example, sold by Ichimaru Pharcos under the name Liquid Botanpi Be.
[0149] Useful skin surfactants include adenosine and its derivatives, as well as retinol and its derivatives, e.g., retinol palmitate; ascorbic acid and its derivatives, e.g., magnesium ascorbyl phosphate and ascorbyl glucoside; tocopherol and its derivatives, e.g., tocopheryl acetate; nicotinic acid and its precursors, e.g., nicotinamide; ubiquinone; glutathione and its precursors, e.g., L-2-oxothiazolidine-4-carboxylic acid, particularly the compound C-glucoside and its derivatives described in EP-1345919, particularly C-beta-D-xylopyranoside-2-hydride described in EP-1345919 Plant extracts including roxypropane, sea fennel and olive leaf extract, as well as plants and their hydrolysates, e.g., rice protein hydrolysate or soy protein; algal extracts and especially kelp, bacterial extracts, sapogenins, e.g., diosgenin and yam plants, especially Japanese yam extract; skin surfactants further include α-hydroxy acids, F3-hydroxy acids, e.g., salicylic acid and N-octanoyl-5-salicylic oligopeptides and pseudodipeptides and their acyl derivatives, especially the acid {2-[acetyl-(3-trifluoromethylphenyl)-amino]-3-methyl-}acetic acid and lipopeptides marketed by the company under the trade names SEDERMA Matrixyl 500 and Matrixyl 3000; lycopene, manganese salts and magnesium salts, especially gluconic acid, and mixtures thereof.
[0150] Adenosine derivatives include, in particular, non-phosphate derivatives of adenosine, such as 2'-deoxyadenosine, 2',3'-adenosine isopropylidene; toyocamycin, 1-methyladenosine, N-6-methyladenosine; adenosine N-oxide, 6-methylmercaptoprin riboside, and 6-chloropurine riboside.
[0151] Other derivatives include adenosine receptor agonists, such as adenosine, adenosine phenylisopropyl ("PIA"), 1-methylisoguanosine, N6-cyclohexyladenosine (CHA), N6-cyclopentyladenosine (CPA), 2-chloro-N6-cyclopentyladenosine, 2-chloroadenosine, N6-phenyladenosine, 2-phenylaminoadenosine, MECA, N6-phenethyladenosine, 2-p-(2-carboxy-ethyl)phenethyl-amino-5'--N-ethylcarboxamideadenosine (CGS-21680), N-ethylcarboxamideadenosine (NECA), 5'(N-cyclopropyl)-carboxamideadenosine, DPMA (PD 129.944), and metrifudil.
[0152] In one embodiment, the composition contains active ingredients that address oily skin. These active ingredients can be lipid-modulating or anti-seborrheic agents capable of regulating the activity of sebaceous glands. These include retinoic acid, benzoyl peroxide, sulfur, vitamin B6 (pyridoxine or) chloride, selenium, samphire--cinnamon extract blend, tea and octanoylglycine, e.g.--Seppic's Sepicontrol A5 TEA---a mixture of cinnamon, sarcosine and octanoylglycine, particularly marketed by Seppic under the trademark name Sepicontrol A5--zinc salts, e.g., zinc gluconate, zinc pyrrolidone carboxylate (or zinc pyridolate), zinc lactate, zinc aspartate, zinc carboxylate, zinc salicylate 20, zinc cysteine;-Derivatives, especially copper and copper pyridolate as Cuivridone Solabia--extracts from the plants Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha pipenta, Rosmarinus officinalis, Salvia officinalis and Thymus vulgaris (all commercially available, for example, by Maruzen)--Spiraea Extracts of ulmaria, e.g., sold by Silab under the name Sebonormine; extracts of the alga Laminaria saccharina, e.g., sold by Biotechmarine under the name Phlorogine; root extracts of burnet (Sanguisorba officinalis / Poterium officinale), ginger rhizome (Gimber officinales), and cinnamon bark (Cinnamomum muscasia), e.g., sold by Solabias under the name Sebustop; flaxseed extract, e.g., sold by Lucas Meyer under the name Linumine; Phellodendron phellodendron extract, e.g., sold by Maruzen under the name Phellodendron extract BG or by Ichimaru Pharcos under the name Phellodendron phellodendron extract B; saw palmetto extract and sesame seed argan oil mixture extract, e.g., Regu Products sold by Pentapharm under the name SEB -- a mixture of extracts of Salvia japonica, Terminalia erythrorhizon, Nasturtium officinale, and bioavailable zinc (microalgae), for example, sold under the name Seborilys Green Tech;-- Extracts of Pygeum afrianum, e.g., sold by Euromed under the name Pygeum afrianum Lipid Steromhea Extract -- Extracts of Selenoa cerulata, e.g., sold by Actives International under the name Viapure Sabal, and sold by Euromed -- Extracts of Plantain Blend, Barberry and Sodium Salicylate 20, e.g., sold under the name Seboclear Rahn -- Clove extract, sold by Maruzen under the name Clove Extract Powder -- Argan oil, e.g., sold under the name Lipofructyl Laboratories Serobiologiques;--Milk protein filtrate, e.g., sold by Sederma under the name Normaseb --Extracts from Laminaria genus seaweed, e.g., sold by Biotechmarine under the name Laminarghane --Oligosaccharides from the seaweed Laminaria digitata, e.g., sold by Codif under the name Phycosaccharide 30 AC --Sugarcane extract, e.g., sold by Sabinsa under the name Policosanol, sulfonated shale oil, e.g., sold by Ichthyol under the name Ichthyol Pale --Extracts from Spiraea japonica, e.g., sold by societeLibiol under the name Cytobiol Ulmaire --Sebacic acid, especially in the form of sodium polyacrylate gel sold by Sederma under the name Sebosoft --Glucomannan extracted from konjac tubers and modified with alkyl sulfonate chains, e.g., sold by Arch under the name Biopol Beta Products sold by Chemical -- extracts of Sophora flavescens, e.g., sold by Bioland under the name Sophora powder or Sophora extract -- extracts of Cinchona bark, e.g., sold by Alban Muller under the name Red Bark HS -- extracts of Panama wood, e.g., sold by Alban Muller under the name Panama wood HS -- glycine transplanted onto undecylen chains, e.g., sold by SEPPIC under the name Lipacide UG OR -- mixtures of oleanolic acid and nordihydroguaiaretic acid, e.g., sold by Sederma in gel form under the name AC.Net; -- phthalimidoperoxyhexanoic acid -- tri(C12~C13) citrate sold by Sasol under the name COSMACOL ECI;This includes trialkyl citrates (C14-C15) sold by Sasol under the name COSMACOL ECL, hydroxydecanoic acid, mixtures of hydroxydecanoic acid, sebacic acid, and 1,10-decanediol, such as those sold by Vincience under the name Acnacidol BG, and mixtures thereof.
[0153] Other dermatolytic agents useful in this specification include N-acetyl-D-glucosamine, panthenol (e.g., DL-panthenol available from Alps Pharmaceutical Inc.), tocopheryl nicotinate, benzoyl peroxide, 3-hydroxybenzoic acid, flavonoids (e.g., flavanone, chalcone), farnesol, phytantriol, glycolic acid, lactic acid, 4-hydroxybenzoic acid, acetylsalicylic acid, 2-hydroxybutanoic acid, 2-hydroxypentanoic acid, 2-hydroxyhexanoic acid, cis-retinoic acid, trans-retinoic acid, retinol, retinyl esters (e.g., retinyl propionate), phytic acid, N-acetyl-L-cysteine, lipoic acid, tocopherol and its esters (e.g., tocopheryl esters) This includes Tate (DL-α-tocopheryl acetate available from Eisai), azelaic acid, arachidonic acid, tetracycline, ibuprofen, naproxen, ketoprofen, hydrocortisone, acetominphen, resorcinol, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, 2,4,4'-trichloro-2'-hydroxydiphenyl ether, 3,4,4'-trichlorocarbanilide, octopirox, lidocaine hydrochloride, clotrimazole, miconazole, ketoconazole, neomycin sulfate, theophylline, and mixtures thereof selected from these.
[0154] In various embodiments, the total amount of dermatolytic agents in the pharmaceutical or cosmetic composition of this disclosure, other than one or more bioactive walnut peptides, is, based on the total weight of the pharmaceutical or cosmetic composition, from more than 0% to about 9% by weight, from more than 0% to about 8% by weight, from more than 0% to about 7% by weight, from more than 0% to about 6% by weight, from more than 0% to about 5% by weight, from more than 0% to about 4% by weight, from more than 0% to about 3% by weight, and from more than 0% to about 2% by weight; from about 10 ppm to about 10% by weight (100,000 ppm), from about 10 ppm to about 5% by weight (50,000 ppm), from about 10 ppm to about 2.5% by weight (25,000 ppm), from about 10 ppm to about 1% by weight (10,000 ppm), from about 10 ppm to about 0.5% by weight (5,000 ppm), and from about 10 ppm to about 0.3% by weight. (3,000 ppm), approximately 10 ppm to approximately 0.2 wt% (2,000 ppm), approximately 10 ppm to approximately 0.1 wt% (1,000 ppm), approximately 10 ppm to 500 ppm; approximately 0.1 to approximately 10 wt%, approximately 0.1 to approximately 5 wt%, approximately 0.1 to approximately 2.5 wt%, approximately 0.1 to approximately 1 wt%, approximately 0.1 to approximately 0.5 wt%, approximately 1 to approximately 10 wt%, approximately 1 to approximately 8 wt%, approximately 1 to It may be contained in amounts of approximately 6% by weight, approximately 1 to approximately 5% by weight, approximately 1 to approximately 4% by weight, approximately 1 to approximately 3% by weight; approximately 2 to approximately 10% by weight, approximately 2 to approximately 8% by weight, approximately 2 to approximately 6% by weight, approximately 2 to approximately 5% by weight, approximately 2 to approximately 4% by weight, approximately 3 to approximately 10% by weight, approximately 3 to approximately 8% by weight, approximately 3 to approximately 6% by weight, approximately 3 to approximately 5% by weight, approximately 4 to approximately 10% by weight, approximately 4 to approximately 8% by weight, or approximately 4 to approximately 6% by weight. [Examples]
[0155] Various modifications can be made to the compositions and methods described above without departing from the scope of the present invention. Accordingly, all disclosures contained in the above description and the following examples are intended to be illustrative and not restrictive.
[0156] Example 1 Reduction of inflammatory cytokines Adult dermal-derived human fibroblasts (Lot 2485, passage 5, Cell Applications) were grown and seeded at a density of 5,000 cells / well in 48-well plates. Cells were expanded and cultured in Eagle's Minimal Essential Medium (EMEM) supplemented with fetal bovine serum (FBS) and penicillin-streptomycin. Cells were allowed to condense overnight, then the medium was aspirated and replaced with medium containing 100 μM or 250 μM of peptide I, peptide II, or peptide III. Except for weekends, the treatment medium was refreshed every other day and the cells were cultured for 4 days. The medium was collected at the end of the culture period. Inflammatory cytokines were quantified by running the LEGENDplex Human Inflammation Panel 1 13-plex (Catalog #740809, Biolegend). Proteins in the culture supernatant were also quantified using the Pierce BCA Protein Assay Kit (Catalog #23225, ThermoFisher). Microsoft Excel and GraphPad Prism were used for additional analysis and data visualization. The amounts of interleukin-6 (IL-6) and interleukin-8 (IL-8) released from adult skin-derived human fibroblasts are shown in Table 1 below, and graphed in Figures 1(a) (IL-6) and 1(b) (IL-8).
[0157] TIFF2026539089000001.tif46170
[0158] Example 2 Increase in growth factors Reconstituted human epidermis (RHE) (EPISKIN / S / 13, Episkin) was received and samples were prepared for use. Upon arrival, the RHE-containing insert was removed from the multiplate and placed in a 12-well plate containing maintenance medium. Untreated control tissues were placed in standard maintenance medium, while the treated groups were placed in maintenance medium containing 250 μM peptide I, II, or III alone or in combination. The medium was aspirated and replaced every other day, except for weekends. The RHE was cultured at 37°C, 5% CO2, and saturated humidity for 7 days at the gas-liquid interface. The medium was collected at the end of the culture period. Growth factors were quantified by running the LEGENDplex Human Growth Factor Panel (Catalog #740809, Biolegend). Proteins in the culture medium supernatant were also quantified using the Pierce BCA Protein Assay Kit (Catalog #741061, ThermoFisher). Microsoft Excel and GraphPad Prism were used for additional analysis and data visualization. The amounts of epidermal growth factor (EGF), hepatocyte growth factor (HGF), and transforming growth factor alpha (TGFa) produced by RHE are shown in Table 2 below and graphed in Figures 2(a)(EGF), 2(b)(HGF), and 2(c)(TGFa).
[0159] TIFF2026539089000002.tif54170
[0160] Example 3 Increase in epidermal stem cells Keratinocyte stem cells (Lot KSC870, passage 2, Bioalternatives) were seeded in 96-well plates and cultured in keratinocyte-SFM supplemented with epidermal growth factor and pituitary extract. After 4 hours, the medium was replaced with a medium containing peptide II or peptide III alone or in combination. Cells were incubated for 96 hours, and the treatment was renewed after 24 hours. After 96 hours, the medium was removed and the cells were fixed with methanol at -20°C. The cells were then stained with Papanicolaou solution for 10 minutes and imaged. The number of holoclones was counted. Data were analyzed and plotted using GraphPad Prism. The number of holoclones relative to the control (normalized) for different concentrations of peptide II, III, and combinations of peptide II and peptide III is shown in Table 3 below. The results are shown graphically in Figure 3.
[0161] TIFF2026539089000003.tif65170
[0162] Example 4 Autophagy induced by aging fibroblasts Adult dermal-derived human fibroblasts (Lot 2485, passage 5, Cell Applications) were grown and seeded at a density of 10,000 cells / well in 12-well glass-bottom plates. Cells were expanded and cultured in Eagle's Minimal Essential Medium (EMEM) supplemented with fetal bovine serum (FBS) and penicillin-streptomycin. Cells were allowed to condense overnight, then the medium was aspirated and replaced with medium containing 100 μM or 250 μM of peptide I, peptide II, or peptide III. Except for weekends, the treatment medium was refreshed every other day, and cells were cultured for 7 days. On day 7, cells were stained and imaged for the presence of autophagy vacuoles according to the Autophagy Assay Kit (ab139484, Abcam) protocol. These images were compared to determine whether the number of autophagy vacuoles increased, decreased, or remained unchanged. The results are reported in Table 4 below. Here, "↑" indicates an increase, "↓" indicates a decrease, and "⇔" indicates no change.
[0163] TIFF2026539089000004.tif51170
[0164] Example 5 Improvement of mitochondrial function in aging fibroblasts Adult dermal-derived human fibroblasts (Lot 2485, passage 5, Cell Applications) were grown and seeded at a density of 10,000 cells / well in 12-well glass-bottom plates. Cells were expanded and cultured in Eagle's Minimal Essential Medium (EMEM) supplemented with fetal bovine serum (FBS) and penicillin-streptomycin. Cells were allowed to condense overnight, then the medium was aspirated and replaced with medium containing 100 μM or 250 μM of peptide I, peptide II, or peptide III. Except for weekends, the treatment medium was refreshed every other day and the cells were cultured for 7 days. On day 7, cells were stained with tetramethylrhodamine ethyl ester (TMRE), and mitochondrial activity was imaged according to the protocol of the TMRE-Mitochondrial Membrane Potential Assay Kit (ab113852, Abcam). The active mitochondria (average intensity normalized to control) were determined and are shown in Table 5 below. The results are shown graphically in Figure 4.
[0165] TIFF2026539089000005.tif53170
[0166] Example 6 differential gene expression The ability of peptides I, II, and III to influence gene expression was investigated in cells at concentrations of 100 μM and 500 μM, and in reconstituted human epidermis (RHE) at 250 μM.
[0167] Adult normal human epidermal keratinocytes Adult normal human epidermal keratinocytes (Lot 80819221, passage 3, ATCC) were expanded and seeded in 6-well plates at a density of 300,000 cells / well. Cells were grown in dermal cell basal medium (ATCC PCS-200-030) supplemented with one Keratinocyte Growth Kit (ATCC PCS-200-040). Cells were fused overnight, then the medium was aspirated and replaced with medium containing 100 μM or 500 μM of peptide I, peptide II, or peptide III. Cells were cultured for 4 days, with the treatment medium being refreshed every other day except for weekends. Following a 7-day incubation period, cells were trypsinized and the cell pellet was snap-frozen using liquid nitrogen. Cells were then subjected to RNA sequencing. For differentially expressed genes (DEGs) related to the skin barrier, the log-2 ratio change in each treatment group compared to an untreated control sample was analyzed. To show the upregulation or downregulation of these genes, the magnification changes were plotted via a heatmap. Microsoft Excel and GraphPad Prism were used for additional analysis and data visualization. The results are shown in the heatmap in Figure 5. The data show that peptides II and III provide a strong benefit to the skin barrier at the cellular level at both concentrations tested, while peptide I showed an effect at higher concentrations.
[0168] Reconstructed human epidermis Reconstituted human epidermis (RHE) (EPISKIN / S / 13, Episkin) was received and samples were prepared for use. Upon arrival, the RHE-containing insert was removed from the multiplate and placed in a 12-well plate containing maintenance medium. Untreated control tissues were placed in standard maintenance medium, while the treatment groups were placed in maintenance medium containing a combination of 250 μM peptides I, II, and III. The medium was aspirated and replaced every other day, except for weekends. RHE was cultured at 37C, 5% CO2, and saturated humidity for 7 days at the gas-liquid interface. Following culture, the samples were snap-frozen in liquid nitrogen and sent for RNA sequencing. For differentially expressed genes (DEGs) related to the skin barrier, the log2 ratio change in each treatment group compared to the untreated control sample was analyzed. To indicate upregulation or downregulation of these genes, the ratio changes were plotted via heatmaps. Microsoft Excel and GraphPad Prism were used for additional analysis and data display, as shown in the heatmap in Figure 6. The data shows that a combination of the three peptides leads to improved skin barrier function in relation to RHE.
[0169] Example 7 Barrier regeneration - Microneedle exvivo model Fresh normal human skin samples were obtained from BioIVT Inc. (Westbury, NY) after abdominal wall reconstruction. The tissue was degreased and blood residue was removed. The tissue was then treated with a microneedle pen (36-pin needle, Dr.Pen A6 Cartridges Tips, Dr.Pen Inc., San Jose, CA, USA) with a needle length of 1.5 mm. The microneedle was passed through the tissue five times. Following the treatment, 1.2 cm diameter epidermal biopsies were prepared and cultured on a gas-liquid contact surface. Skin grafts that had not undergone microneedling were used as untreated controls. The control and microneedle control samples were cultured in Dulbecco's Modified Eagle's Medium (DMEM containing 650 μL per well, 10% fetal bovine serum and 1% penicillin-streptomycin) at 37°C and 5% CO2. Microneedle samples treated with peptides were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin. Each peptide was dissolved in the culture medium at a concentration of 500 μM. The treatment medium was changed every other day, except on weekends. Following a 7-day culture period, all biopsies were processed for histological and immunohistochemical analysis. Skin grafts were processed for hematoxylin and eosin (H&E) staining for filaggrin (FLG) and transglutaminase 1 (TGM1), as well as for immunohistochemical staining, according to the standard protocol (HistoWiz, Brooklyn, NY).
[0170] Histological analysis reveals the overall tissue structure and integrity. Samples subjected to microneedle treatment show the presence of microperforations, as shown in Figure 7. There is no evidence of vacuole formation or epidermal cell stress in any of the samples.
[0171] Transglutaminase-1 is an enzyme typically expressed locally in the upper granular layer, which is involved in the formation of the keratinocyte envelope. Typical localization is shown by red staining of the untreated control. Microneedling treatment reduces expression in the micro-wound area. Treatment with 500 μM of peptides 1, 2, and 3, either alone or in combination, increases TGM1 expression and localization. Filaggrin, on the other hand, is an essential protein for epidermal differentiation and is important for proper skin barrier function. Filaggrin is typically expressed in the stratum corneum and upper granular layer, as shown by red staining of the untreated control. Similar to TGM1, microneedling inhibits filaggrin expression around the micro-wound area due to the disruption of the skin barrier. Treatment with 500 μM of peptides 1, 2, and 3, either alone or in combination, increases filaggrin expression. Together with the TGM1 data, this suggests that the peptides may play a role in promoting barrier regeneration and barrier function after microneedling.
[0172] Example 87 Ex vivo chronic inflammation model Fresh normal human skin samples were obtained from BioIVT Inc. (Westbury, NY) after abdominal wall reconstruction. The tissue was degreased and blood residues were removed. 1.2 cm diameter epidermal biopsies were prepared and cultured on a gas-liquid contact surface. Skin grafts that had not been subjected to inflammatory stimulants were used as untreated controls. Control samples were cultured in Dulbecco's Modified Eagle's Medium (DMEM containing 650 μL per well, 10% fetal bovine serum and 1% penicillin-streptomycin) at 37°C and 5% CO2. Microneedle samples treated with peptides were cultured in DMEM containing 10% fetal bovine serum and 1% penicillin-streptomycin, diluted 2 times to a 500-fold cell stimulation cocktail (CSC). The peptide-treated samples contained 500 μM of each peptide dissolved in the culture medium. Fresh stimulants were prepared every other day, except on weekends, by replenishing the treatment medium each time. Following a 7-day culture period, all biopsies were subjected to histological and immunohistochemical analysis. Skin grafts were treated for hematoxylin and eosin (H&E) staining for filaggrin (FLG) and transglutaminase 1 (TGM1), as well as immunohistochemical staining, according to the standard protocol (HistoWiz, Brooklyn, NY).
[0173] Histological analysis reveals the overall tissue structure and integrity, as shown in Figure 8. No evidence of vacuolation or epidermal cell stress was present in any of the untreated control samples. However, treatment with the inflammatory stimulant CSC showed signs of epidermal stress, along with signs of spongiformity / vacuum formation. These effects were mitigated by treatment with 500 μM peptides 1, 2, and 3, both individually and in combination.
[0174] Impaired barrier function typically manifests in different inflammatory skin conditions. This is because a close link is suggested between the release of various inflammatory cytokines accompanied by abnormal or altered lipid composition and the disruption of key barrier-related proteins. Therefore, changes in barrier markers are expected in inflammatory skin conditions. Samples treated with CSC inflammatory stimulants showed changes in TGM1 and filaggrin expression (increased expression and localization). However, treatment with peptides alone and in combination showed similar phenotypes to our untreated controls, suggesting that these peptides may reduce inflammation-related barrier disruption.
[0175] Example 9 Facial treatment An exemplary facial treatment containing approximately 0.01 to 1% by weight of peptide I, peptide II, peptide III, or a combination thereof is shown below.
[0176] TIFF2026539089000006.tif39170
[0177] The foregoing description explains and describes the present disclosure. In addition, the present disclosure shows and describes only preferred embodiments. However, as stated above, it should be understood that the present disclosure is applicable in various other combinations, modifications, and environments, and is modifiable or adapted within the scope of the concept of the invention as expressed herein, and is corresponding to the above teachings and / or skills or knowledge of the relevant art. The embodiments described herein are intended to further illustrate the best modes known to the applicant and to enable those skilled in the art to utilize the present disclosure, including various modifications necessary for their particular use or application in such embodiments or other embodiments. Accordingly, this description is not intended to limit the invention to the forms disclosed herein. Furthermore, the claims are intended to be construed as including alternative embodiments.
[0178] As used herein, the terms “comprising,” “having,” and “including” are used in an open and non-restrictive sense.
[0179] It should be understood that the words “a, an” and “the” encompass both singular and plural forms. Therefore, the expression “these mixtures” also refers to multiple “these mixtures.” Throughout this disclosure, the expression “these mixtures” is used in accordance with the list of elements shown in the following example, where the letters A-F represent elements: “one or more elements selected from the group consisting of A, B, C, D, E, F and mixtures thereof.” The expression “these mixtures” does not require that the mixtures contain all of A, B, C, D, E, and F (although they may contain all of A, B, C, D, E, and F). Rather, it indicates that any two or more mixtures of A, B, C, D, E, and F may be included. That is, it is equivalent to the phrase “one or more elements selected from the group consisting of A, B, C, D, E, F and mixtures of any two or more of A, B, C, D, E, and F.”
[0180] Similarly, the expression “the salt” can refer to multiple “the salts.” Therefore, where this disclosure refers to “elements selected from the group consisting of A, B, C, D, E, F, and their salts and mixtures thereof,” it may include one or more of A, B, C, D, and F; one or more of salts of A, B, C, D, E, and F; or a mixture of any two of A, B, C, D, E, F, salts of A, B, C, D, E, and F.
[0181] The salts referred to throughout this disclosure may include salts having counterions such as alkali metals, alkaline earth metals, or ammonium counterions. However, this list of counterions is not limiting. Suitable counterions for the components described herein are known in the art.
[0182] The expression "one or more" means "at least one," and therefore includes individual components and mixtures / combinations.
[0183] The term "plural" means "more than one" or "two or more."
[0184] Unless otherwise indicated in the examples, all numbers expressing the amounts of components and / or reaction conditions may be modified in all cases by the term "approximately," meaning within + / - 5% of the indicated number.
[0185] All percentages, parts, and ratios in this specification are based on the total weight of the compositions of the present invention unless otherwise indicated.
[0186] Some of the various categories of identified components may overlap. If overlap exists and a composition contains both components (or more than two overlapping components), the overlapping compound does not represent multiple components. For example, some compounds may be considered both emollients and nonionic surfactants. If a particular composition contains both emollients and nonionic surfactants, a single compound will either act as an emollient only or as a nonionic surfactant only (a single compound will not simultaneously perform the roles of both an emollient and a nonionic surfactant).
[0187] As used herein, all ranges provided are intended to include all combinations of specific ranges within a given range, and subranges between given ranges. Thus, the range 1–5 specifically includes 1, 2, 3, 4, and 5, as well as subranges such as 2–5, 3–5, 2–3, 2–4, and 1–4. All ranges and values disclosed herein are inclusive and combinable. For example, any value or point described herein that falls within a range described herein may function as a minimum or maximum value for deriving subranges, etc.
[0188] As used herein, the expressions “substantially absent” or “essentially absent” mean that the weight of a particular material added to the composition is less than about 2% based on the total weight of the composition. However, the composition may contain less than about 1% by weight, less than about 0.5% by weight, or less than about 0.1% by weight of a particular material, or may contain no particular material at all.
[0189] All components positively presented in this disclosure may be negatively excluded from the claims. For example, a claimed composition may be “free,” “essentially free” (or “substantially free”) of one or more components positively presented in this disclosure.
[0190] All publications and patent applications cited herein are incorporated herein by reference in whole for any and all purposes, to the extent that each individual publication or patent application is specifically and individually indicated as being invoked by reference. In the event of any conflict between this disclosure and any publication or patent application incorporated herein by reference, this disclosure shall prevail.
Claims
1. A method for treating skin, comprising applying one or more therapeutically effective amounts of bioactive walnut peptides topically to the skin.
2. The method according to claim 1, wherein one or more bioactive walnut peptides have a molecular weight of less than 5,000 daltons, preferably less than 2,000 daltons, and more preferably less than 1,000 daltons.
3. The method according to claim 1 or 2, wherein one or more bioactive walnut peptides have 2 to 20 amino acid residues, preferably 3 to 15 amino acid residues, and more preferably 4 to about 10 amino acid residues.
4. The method according to any one of claims 1 to 3, wherein one or more bioactive walnut peptides comprise one or more amino acids selected from leucine, proline, and combinations thereof, and preferably, one or more bioactive walnut peptides comprise three or more amino acids selected from leucine, proline, or combinations thereof.
5. The method according to any one of claims 1 to 4, wherein one or more bioactive walnut peptides comprise an amino acid sequence selected from Leu-Pro-Leu, Leu-Leu-Pro, Pro-Pro-Leu, or Pro-Leu-Pro, and preferably one or more bioactive walnut peptides comprise an amino acid sequence selected from Thr-Trp-Leu-Pro-Leu-Pro-Arg, Tyr-Val-Leu-Leu-Pro-Ser-Pro-Lys, or Lys-Val-Pro-Pro-Leu-Leu-Tyr.
6. One or more bioactive walnut peptides, Peptide I TWLPLPR (Thr-Trp-Leu-Pro-Leu-Pro-Arg), Peptide II YVLLPSPK (Tyr-Val-Leu-Leu-Pro-Ser-Pro-Lys), Peptide III KVPPLLY (Lys-Val-Pro-Pro-Leu-Leu-Tyr), or combinations thereof. The method according to any one of claims 1 to 5, selected from the following.
7. The method according to any one of claims 1 to 6, comprising applying a combination of two or more bioactive walnut peptides to the skin topically, preferably comprising applying three or more bioactive walnut peptides topically.
8. (a) To improve the appearance of the skin, (b) To reduce, treat, and / or prevent skin aging and / or the effects of skin aging, (c) Increase the proliferation of fibroblasts (d) Stimulates the proliferation, movement, morphogenesis, and / or angiogenesis of epithelial cells, (e) Promote the migration of fibroblasts, (f) To increase the abundance or synthesis of hyaluronic acid, and / or increase the synthesis or abundance of collagen, elastin, and / or fibronectin. (g) Improves skin elasticity, (h) Improve autophagy in cutaneous fibroblasts (i) Enhance ceramide synthesis (ACER1), (j) Promotes terminal differentiation (involucrin (IVL), loricrin (Lor), and transglutaminase 1 (TGM1)), (k) Increase keratinization (KRT) (l) Promotes late keratinocyte envelope formation (LCE), and / or (m) Increase the abundance or synthesis of small proline-rich proteins (SPRRs), The method according to any one of claims 1 to 7.
9. To reduce, treat, or prevent the production, release, or abundance of inflammatory cytokines in the skin, preferably interleukin-6 (IL-6), interleukin-8 (IL-8), or combinations thereof. To enhance the production, release, or abundance of epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor alpha (TGFa), or combinations thereof in the skin. For example, in aging or senescent fibroblasts, enhance, induce, and / or increase autophagy in the skin. For example, in aging or senescent fibroblasts, improve mitochondrial function and / or activity of the skin. To improve skin barrier function or skin re-epithelialization, and / or Enhances terminal differentiation and keratinization of skin cells. The method according to any one of claims 1 to 8.
10. A method according to any one of claims 1 to 7 for treating damaged skin.
11. The method according to claim 10, wherein the damaged skin is physical damage, chemical damage, environmental damage, sun damage, damage caused by disease, or a combination thereof.
12. To improve wound healing, (i) damaging skin tissue using chemicals, lasers, or physical force, and (ii) Applying one or more bioactive walnut peptides in a therapeutically effective amount to the damaged skin. The method according to any one of claims 1 to 7, including
13. The method according to claim 12, wherein skin tissue is damaged using an ablative laser treatment, a non-ablative laser treatment, microneedling treatment, cryotherapy treatment, radiofrequency microneedling treatment, dermabrasion, chemical peeling, exfoliating agent, or mechanical device that damages the skin.
14. The method according to any one of claims 1 to 7, for improving the skin barrier function in healthy, unimpaired skin.
15. The method according to any one of claims 1 to 7, for treating a skin condition, disease, or disorder selected from psoriasis, dermatitis, atopic dermatitis, allergic dermatitis, eczema, spongy condition, edema, hereditary ichthyosis, senile xerosis, palmar keratosis, plantar keratosis, wounds, contusions, pore size, skin cancer, impaired healing or re-epithelialization, keloids, hypertrophic scars, cellulitis, orange peel skin, increased elasticity, increased photoelasticity, keratosis, acne erythematous, tubulectosis, telangiectosis, or a combination thereof.
16. The method according to any one of claims 1 to 7, wherein the skin requiring treatment is inflamed or suffering from an inflammatory condition.
17. The method according to claim 16, wherein the inflammatory condition is selected from atopic dermatitis, psoriasis, or a combination thereof.
18. The method according to any one of claims 1 to 17, comprising applying a combination of two or more bioactive walnut peptides topically to the skin, wherein the topical application of the combination of two or more bioactive walnut peptides provides a synergistic effect greater than the sum provided by the topical application of corresponding amounts of individual bioactive walnut peptides, preferably the synergistic effect being at least 5%, preferably at least 10%, and more preferably at least 25% greater than the sum.
19. The method according to any one of claims 1 to 18, comprising applying two or more bioactive walnut peptides, preferably three or more bioactive walnut peptides, to the skin topically, wherein the two or more bioactive walnut peptides include a first bioactive walnut peptide and a second bioactive walnut peptide, and the weight ratio of the first bioactive walnut peptide to the second bioactive walnut peptide is about 1:10 to about 10:1, preferably about 1:5 to about 5:1, more preferably about 1:2 to about 2:1, and even more preferably about 1:
1.
20. The method involves topically applying a combination of three or more bioactive walnut peptides to the skin, wherein the three or more bioactive walnut peptides include a first bioactive walnut peptide, a second bioactive walnut peptide, and a third bioactive walnut peptide. (i) The weight ratio of the first bioactive walnut peptide to the second bioactive walnut peptide is about 1:10 to about 10:1, preferably about 1:5 to about 5:1, more preferably about 1:2 to about 2:1, and even more preferably about 1:
1. (ii) The weight ratio of the first bioactive walnut peptide to the third bioactive walnut peptide is about 1:10 to about 10:1, preferably about 1:5 to about 5:1, more preferably about 1:2 to about 2:1, and even more preferably about 1:
1. (iii) The weight ratio of the second bioactive walnut peptide to the third bioactive walnut peptide is about 1:10 to about 10:1, preferably about 1:5 to about 5:1, more preferably about 1:2 to about 2:1, and even more preferably about 1:
1. The method according to any one of claims 1 to 19.
21. The method according to any one of claims 1 to 20, wherein one or more bioactive walnut peptides are applied topically in a topical composition comprising about 0.001 to about 10% by weight, preferably about 0.05 to about 8% by weight, more preferably about 0.1 to about 5% by weight, and a physiologically acceptable carrier.
22. The method according to claim 21, wherein the topical composition is a lotion, cream, serum, spray, emulsion, gel, powder, dispersion, ointment, spray, sticks, paste, or foam.
23. The method according to any one of claims 1 to 22, wherein one or more bioactive walnut peptides are combined with one or more additional dermatolytic agents.
24. The method according to claim 23, wherein one or more additional skin activators are selected from anti-atrophic agents, antioxidants, depigmentants, or combinations thereof.
25. The method according to claim 23, wherein one or more additional skin activators are selected from ceramide, 2-mercaptonitinoylglycine, alpha hydroxy acid, beta hydroxy acid, vitamin A, vitamin C, vitamin D, vitamin E, niacinamide, caffeine, ferulic acid, salicylic acid, madecassoside, retinoic acid, benzoyl peroxide, or a combination thereof.
26. The method according to claim 25, wherein one or more additional skin activators comprise one or more ceramides.
27. The method according to claim 26, wherein one or more ceramides are selected from ceramide EOP, ceramide AS, ceramide AP, ceramide NS, ceramide NP, ceramide NH, ceramide AH, ceramide EOH, ceramide EOS, ceramide AdS, ceramide NdS, ceramide EOdS, or a combination thereof.
28. The method according to any one of claims 1 to 7 and 18 to 27, which involves decolorizing the skin, whitening the skin, making the skin appear brighter, treating hyperpigmentation, treating melasma, or a combination thereof.
29. The method according to any one of claims 1 to 7 and 18 to 27, for evening out skin tone.
30. A topical composition comprising one or more bioactive walnut peptides as described in any one of claims 1 to 6, or one or more bioactive walnut peptides for use in skin treatment, preferably for use in the method according to any one of claims 1 to 30.
